19-23 April 2017 Amsterdam
THU-001 | Risk factors of early emergent hospital readmission and 6-month mortality in patients with cirrhosis after a recovery from bacterial or fungal infection | Filippo Morando | Received |
SAT-001 | Human umbilical cord mesenchymal stem cell treatment improves survival rate in patients with decompensated liver cirrhosis | Ming Shi | Received |
SAT-002 | Cirrhosis and acute on chronic liver failure: is ammonia a predictor of hepatic encephalopathy and mortality? | Mohammed Sheikh | Received |
THU-002 | Pregnancy in women with idiopathic non-cirrhotic portal hypertension: results of a multicentric European study on maternal and fetal management and outcome | Filipe Teixeira Andrade | Received |
FRI-002 | Macrophage activation markers sCD163 and mannose receptor predict survival and correlate with markers of gut permeability in patients with liver cirrhosis | Florian Rainer | Received |
FRI-003 | Non malignant portal vein thrombosis in cirrhotic patients: is the anticoagulation safe and efficient? | Gargouri Dalila | Received |
THU-003 | Von Willebrand Factor as a predictor of short-term morbidity and mortality in comparison with conventional scoring systems | Aditya Vivekanand Kulkarni | Received |
THU-004 | Early initiation of carvedilol is safe and cost effective in cirrhotic patients presenting with upper GI bleed following endoscopic therapy: results of a prospective randomized trial | Adnan Salim | Received |
SAT-004 | Prolonged intensive care support of patients with acute on chronic liver failure and CLIF-C ACLF score greater than 70 may be futile | Nekisa Zakeri | Received |
SAT-005 | Transjugular intrahepatic portosystemic shunt before planned abdominal surgery in cirrhotic patients | Nicolas Tabchouri | Received |
THU-005 | Platelet count, spleen length and platelet count/spleen length ratio for the diagnosis of oesophageal varices in patients with hepatic cirrhosis. A systematic review and meta-analysis | Agostino Colli | Received |
FRI-006 | Validation of the Baveno VI criteria for the screening of gastroesophageal varices in our hospital | Gema Molina Arriero | Received |
THU-006 | Rapid change of liver stiffness after variceal ligation and TIPS implantation | Felix Piecha | Received |
SAT-006 | Farnesoid-X Receptor single nucleotide polymorphism rs35724 is potentially associated with patients` outcome in decompensated liver cirrhosis | Cornelius Engelmann | Received |
SAT-007 | The long-term impact of sustained virologic response (SVR) on patient-reported outcomes (PROS) in cirrhotics with Hepatitis C (HCV) infection | Zobair M Younossi | Received |
FRI-007 | Abnormal MOCA scores are common and predict morbidity and mortality in patients with cirrhosis | Michael Ney | Received |
THU-007 | A chronic disease management model for chronic liver failure is cost-effective; cost-effectiveness analysis | Alan J Wigg | Received |
THU-008 | Spontaneous bacterial empyem revisited | Alberto Amador | Received |
FRI-008 | Porto- systemic shunt embolization and recurrent ascites: a single centre case series | Graziella Privitera | Received |
SAT-008 | Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials | Nina Kimer | Received |
FRI-009 | Early recurrent overt hepatic encephalopathy is associated with poor survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt | Guohong Han | Received |
THU-009 | Outcome of liver transplant recipients after the first episode of bacterial infection | Alberto Ferrarese | Received |
SAT-009 | New classification of gastric varices: a twenty-year experience | Nipun Verma | Received |
THU-010 | Decreased hypercoagulable state in hepatitis C virus-cirrhotic patients treated with DAA: the outcome revolution | Alberto Zanetto | Received |
FRI-010 | Hepatic encephalopathy in cirrhotic patients with bacterial infections: prevalence, clinical characteristics and correlation with prognosis: a prospective study | Gustavo Henrique Santos Pereira | Received |
FRI-011 | Serum creatinine level is not appropriate in predicting prognosis in patients with liver cirrhosis and sarcopenia | Han Ah Lee | Received |
THU-011 | Long-term survival after hospital discharge in cirrhotic patients previously hospitalized in intensive care unit for an acute event: a 6 year cohort study | Fabien Marquion | Received |
SAT-011 | Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF | Vinod Arora | Received |
SAT-012 | Non-invasive tools to ruling out large varices: RESIST-HCV vs. Baveno VI criteria in a large cohort of patients with HCV cirrhosis | Vincenza Calvaruso | Received |
THU-012 | Usefulness of the six-minute walk as a predictor of mortality in patients with decompensated cirrhosis | Ernesto Marquez Guillen | Received |
FRI-012 | time in HE in cirrhotic patients with an acute episode (=grade 2) determines short and long-term survival | Meritxell Ventura Cots | Received |
FRI-013 | Palliative care access for hospitalized patients with end stage liver disease across the United States | Mayur Brahmania | Received |
THU-013 | High serum human beta-defensin-1 is associated with increased short-term mortality in patients with decompensated cirrhosis | Alexandra Alexopoulou | Received |
THU-014 | Prospective study of gastrointestinal tract colonization with multidrug resistant bacteria and potential association with infection development and survival in patients with decompensated cirrhosis | Alexandra Alexopoulou | Received |
FRI-014 | Cirrhotic patients in ICU with gastro-intestinal bleeding managed according to recent guidelines display altered brain hemoglobin oxygen´s saturation assessed by near infrared spectroscopy | Maxime Mallet | Received |
SAT-014 | Decrease in cardiac work in patients with alcoholic hepatitis: role of inflammation? | Olivier Roux | Received |
FRI-015 | Von Willebrand factor antigen predicts portal hypertensive bleeding, infections, and survival, independently of portal hypertension severity | Mattias Mandorfer | Received |
THU-015 | Single center validation of scores for prediction of mortality in patients with acute-on-chronic liver failure or acute decompensation of cirrhosis without acute-on-chronic liver failure | Alexandra Alexopoulou | Received |
SAT-015 | PALBI - the platelet-albumin-bilirubin score – a better predictor of outcome of acute variceal bleeding | Omar Elshaarawy | Received |
THU-016 | Uncontrolled glycaemia increases the risk of developing spontaneous bacterial peritonitis in patients with cirrhosis | Fatima Higuera-de La Tijera | Received |
FRI-016 | Performance of FibroScan to detect large esophageal varices in chronic liver diseases is improved by a novel spleen-dedicated examination | Horia Stefanescu | Received |
SAT-016 | Prevalence and clinical impact of rectal colonization by multidrug-resistant bacteria in critically ill patients with and without cirrhosis | Veronica Enith Prado Gonzalez | Received |
SAT-017 | Real world impact of rifaximin-a use in hepatic encephalopathy patients with advanced liver disease or continued alcohol misuse: a post-hoc analysis of the IMPRESS study | Paola Di Maggio | Received |
THU-017 | Metabolic risk factors increase the risk of hepatocellular carcinoma in patients with hepatitis C cirrhosis | Alina Kutsenko | Received |
FRI-018 | Presepsin (soluble CD14 subtype) levels in cirrhotic patients with bacterial infections and/or portal hypertension related bleeding presented with or without acute kidney injury | Ioannis S Elefsiniotis | Received |
SAT-018 | The addition of splenic and superior mesenteric vein respiratory excursions to Baveno VI criteria can save more endoscopies without compromising its diagnostic accuracy | Paolo Del Poggio | Received |
THU-018 | GAVE is more common in patients with NASH-cirrhosis | Aline LeCleac´h | Received |
SAT-019 | Screening of large esophageal varices by a simple algorithm of blood markers | Paul Cales | Received |
THU-019 | Mortality of variceal bleeding admitted to the intensive care unit: an Australasian study | Ammar Majeed | Received |
FRI-019 | Adipocyte fatty acid binding protein in cirrhosis: increased hepatic gene expression and plasma levels and correlation with clinical outcomes | Isabel Graupera | Received |
FRI-020 | A multimodality assessment of liver fibrosis in asymptomatic Fontan patients | Isabelle Munsterman | Received |
SAT-020 | Fat mass and visceral fat inversely correlate with disease severity in patients with liver cirrhosis - a Bioelectrical impedance analysis based study | Varsha Shasthry | Received |
THU-020 | C reactive protein contributes to the early prediction of 90-day mortality risk in acutely decompensated cirrhotic patients | Ana Clemente | Received |
THU-021 | Hepatic and non-hepatic events after obtaining a SVR in patients with genotype 1b liver cirrhosis-short time follow-up-single center experience | Ana Maria Singeap | Received |
FRI-021 | Short-term metabolic alterations following liver transplantation | Iva Košuta | Received |
THU-022 | The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy | Andrei Mihai Voiosu | Received |
FRI-022 | NACSELD acute-on-chronic liver failure (NACSELD-ACLF) predicts 30-day mortality in admitted cirrhotic patients | Jacqueline G Oleary | Received |
SAT-022 | DASIMAR - a novel prognostic biomarker for acute cirrhosis decompensation to guide early intervention - a prospective multicenter study | Peter Holland-Fischer | Received |
SAT-023 | For diagnosis of acute kidney injury in decompensated cirrhosis the estimation of baseline serum creatinine using Modification of Diet in Renal Disease formula is not accurate enough | Petra Fischer | Received |
THU-023 | Adverse events and the development of acute on chronic liver failure in patients with cirrhosis undergoing endoscopic retrograde cholangiopancreatography: A retrospective, multicenter, case-control study | Andres Cardenas | Received |
FRI-023 | When to refer end-stage liver disease patients to palliative care: a survey of practicing liver and palliative care clinicians | James Philip Esteban | Received |
FRI-024 | An Innovative app focused on patients and caregivers significantly decreases avoidable and HE-related readmissions in cirrhotic patients | Jasmohan Singh Bajaj | Received |
THU-024 | Intestinal colonisation by Veillonella spp. is predictive for mortality in stable cirrhosis and could be partially reduced by a multispecies probiotic in a randomized placebo controlled trial | Angela Horvath | Received |
SAT-024 | The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease | Philip Georg Ferstl | Received |
THU-025 | Prevalence of portal trombosis related to the degree of portal hypertension | Joaquin Cabezas Gonzalez | Received |
FRI-025 | Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatients | Jasmohan S Singh Bajaj | Received |
THU-026 | The natural history of covert hepatic encephalopathy in cirrhotic patients in a tertiary care hospital | Anjiang Wang | Received |
FRI-026 | Oral glutamine challenge predicts risk and defines hepatic encephalopathy types | Javier Ampuero | Received |
SAT-026 | Hepatocyte microvesicle levels predict 6-month survival in patients with cirrhosis: results of a prospective study on 242 patients | Pierre-Emmanuel Rautou | Received |
FRI-027 | Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis | Javier Fernandez | Received |
THU-027 | Long-term prognosis following acute-on-chronic liver failure | Eileen L. Yoon | Received |
SAT-027 | Modification of deranged systemic hemodynamic parameters and impaired intestinal permeability with slow infusion of furosemide and albumin with or without terlipressin in patients with refractory ascites | Prabhat Narain Sharma | Received |
THU-028 | Clinical significance of urinary neutrophil gelatinase-associated lipocalin measurement in differentiating various etiologies of acute kidney injury in cirrhotic patients | Eileen L. Yoon | Received |
FRI-028 | The Quick SOFA, a simple bedside score, identifies hospitalized cirrhotic patients with poor outcomes | Jean-Paul Cervoni | Received |
SAT-028 | Impact of antiviral treatment in patients with HCV cirrhosis: a reduction in hospital admission rates | Prashant Bamania | Received |
SAT-029 | Occult advanced fibrosis in the general population | Rifaat Safadi | Received |
THU-029 | Bacterial deoxyribonucleic is frequent in blood samples of patients with compensated cirrhosis and obesity and is associated with lack of decrease of portal pressure after an intensive lifestyle intervention | Annalisa Berzigotti | Received |
SAT-030 | Carvedilol is associated with improved survival in patients with decompensated cirrhosis | Rohit Sinha | Received |
THU-030 | L-ornithine L-aspartate for hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials | Ee Teng Goh | Received |
THU-031 | Nutritional habits in patients with chronic liver disease: adherence of real life diet to international guidelines and its association with disease stage | Edoardo Poli | Received |
SAT-031 | Frequency and causes of malnutrition in liver disease patients: results from a multi-centric cross-sectional survey from gastroenterology tertiary clinics | Roxana Vadan | Received |
FRI-031 | Performance of upper gastrointestinal bleeding risk assessment scores in variceal bleeding: a prospective international multicenter study | Yung Ka Chin | Received |
THU-032 | Resistant bacterial infections in cirrhosis: a French observational prospective multicentre nationwide study (RESIST study) | Arnaud Pauwels | Received |
SAT-033 | Assessment of Sepsis-3 criteria in patients with cirrhosis and bacterial infections | Salvatore Piano | Received |
FRI-033 | Acute hemodynamic response to beta-blockers: factors influencing its outcome | Antonio Cuadrado Lavin | Received |
FRI-034 | Patients with alcoholic-related cirrhosis have high burden of coronary arteriosclerosis compared to non-alcohol-related cirrhosis | Karen Vagner Danielsen | Received |
SAT-034 | Impact of acute-on-chronic liver failure on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome | Salvatore Piano | Received |
THU-034 | Systematic review with meta-analysis: liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding | Astrid Marot | Received |
THU-035 | A new classification of chronic portal vein occlusion for assessing the feasibility of recanalization in non-cirrhotic patients | Astrid Marot | Received |
SAT-035 | Prediction in-hospital mortality of acute esophagogastric variceal bleeding: which is the best score? | Sara Monteiro | Received |
THU-036 | Bioelectrical impedance vector analysis is an objective method for nutritional assessment in patients with cirrhosis | Astrid Ruiz-Margáin | Received |
FRI-036 | Medication beliefs predict low medication adherence in people with decompensated cirrhosis | Kelly Lee Hayward | Received |
FRI-037 | The association between serum sodium and rate of hepatic encephalopathy in cirrhosis patients with ascites | Lars Bossen | Received |
THU-037 | Comparison of heterozygous alpha-1 antitrypsin deficiency in unselected patients with liver cirrhosis and transplant recipients with the general population and liver donors | Benedikt Schaefer | Received |
THU-038 | The effect of planned care on resource use and end of life outcomes in patients with diuretic resistant ascites: a retrospective cohort study of deaths in England | Benjamin Hudson | Received |
FRI-038 | Presence of ACLF is the best predictor of mortality in patients with decompensated chronic liver disease managed in a non-specialist environment | Laura Burke | Received |
FRI-039 | Maternal and pregnancy outcomes in women with cirrhosis: Room for optimizing care | Mary Rinella | Received |
THU-039 | Human ascites microfibril-associated protein 4 is an independent predictor of mortality in decompensated cirrhosis | Bjørn Stæhr Madsen | Received |
SAT-039 | HCV cirrhosis: liver volume as a non-invasive predictor of liver recovery post DAA treatment | Tommaso Di Maira | Received |
SAT-040 | Malnutrition is an independent predictor of immune dysfunction in cirrhotic patients | Siddharth Sood | Received |
THU-040 | New International club of ascites definition of acute kidney injury applied at admission is not independently associated with mortality in patients with acute-on-chronic liver failure | C Ganesh Pai | Received |
FRI-040 | Prospective study to evaluate the resolution of minimal hepatic encephalopathy after antiviral treatment in patients with HCV liver cirrhosis | Marta Hernandez Conde | Received |
FRI-041 | Rifaximin-a is associated with reductions in emergency department resource use in UK patients with hepatic encephalopathy: real world evidence from the IMPRESS study | Mark Hudson | Received |
THU-041 | Hepatic hydrothorax in patients with cirrhosis and ascites – its prevalence and association with other cirrhosis complications | Daniela Matei | Received |
SAT-041 | Albumin-bilirubin grade allows accurate prediction of live births in patients with liver disease | Tiong Yeng Lim | Received |
SAT-042 | Alcoholic cirrhosis is not a risk factor for acute myocardial infarction: a nationwide cohort study | Thomas Deleuran | Received |
THU-042 | Proton pump inhibitors increase the risk for hepatic encephalopathy in patients with cirrhosis and ascites | Daniela Matei | Received |
FRI-042 | A standardized CT estimation of liver volume is associated to the severity of cirrhosis and predicts the risk of decompensation | Ana Clemente | Received |
FRI-043 | Cellulitis is a common precipitant of acute kidney injury and mortality in patients with cirrhosis | Luis Téllez | Received |
THU-043 | Ethnic differences in overall survival of patients with cirrhosis: results of a cohort of 2939 United States patients with long-term follow-up | Pauline Nguyen | Received |
SAT-043 | Sarcopenia represents a risk factor for the development of hepatic encephalopathy after transjugular intrahepatic portosysthemic shunt | Silvia Nardelli | Received |
SAT-044 | Effect of spontaneous bacterial peritonitis on mortality among patients with alcoholic cirrhosis and ascites | Thomas Deleuran | Received |
THU-044 | Evaluation of the CLIF-C ACLF score in critically ill cirrhotic patients in intensive care units in Europe and North America: a multicenter cohort study | Constantine Jason Karvellas | Received |
FRI-044 | Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life: an international cohort study | Macarena Simón-Talero | Received |
FRI-045 | Non-invasive measures to predict the presence of oesophageal varices in real life practice | Mafalda Sousa | Received |
THU-045 | Urinary MicroARNs as potential biomarkers to predict the evolution of kidney function after liver transplantation in patients with cirrhosis | Clement Lejealle | Received |
SAT-045 | The optimal dose of concomitant albumin for the treatment of hepatorenal syndrome type 1 - what is it? | Stephen Chris Pappas | Received |
SAT-046 | Bacterial infections in cirrhosis – a retrospective analysis updating on microbiology and resistance rates | Theresa Bucsics | Received |
THU-046 | The impact of esophageal varices on the prognosis of patients with hepatocellular carcinoma after surgical resection: A propensity score matching analysis | Chung-Yu Chang | Received |
FRI-046 | GR3027 reverses neurosteroid-induced, GABAA receptor-mediated inhibition of brain function: A human challenge study | Maja Johansson | Received |
FRI-047 | Changes in the model for end-stage liver disease (MELD) scores on day 7 predict mortality in acute on chronic liver disease: the delta-MELD project | Majd B Protty | Received |
SAT-047 | Efficacy of nutritional therapy on quality of life in liver cirrhosis with minimal hepatic encephalopathy- randomized controlled trial | Sudhir Maharshi | Received |
THU-047 | Not all of the patients with hepatitis B-related hepatocellular carcinoma require endoscopic screening for esophageal varices: a large cohort study | Chung-Yu Chang | Received |
THU-048 | End-stage cirrhotic patients rarely receive adequate palliative care. Can we do something earlier? | Chun-Han Cheng | Received |
SAT-048 | The National Early Warning Score accurately discriminates the risk of serious in-hospital adverse outcomes in patients with liver disease | Therasa J. Hydes | Received |
FRI-048 | Effect of terlipressin treatment in liver transplant-eligible patients with hepatorenal syndrome | Marc Nguyen-Tat | Received |
FRI-049 | Prevalence and clinical implications of hemophagocytic syndrome in patients with infection-induced acute on chronic liver failure – a retrospective pilot study | Mariana Verdelho Machado | Received |
THU-049 | External validation of a new equation predicting glomerular filtration rate in patients with cirrhosis candidates for liver transplantation and impaired renal function | Claire Francoz | Received |
SAT-049 | Proton pump inhibitors are associated with a higher risk for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites | Tammo Lambert Tergast | Received |
SAT-050 | Predictors of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis and ascites | Tammo Lambert Tergast | Received |
FRI-050 | The emerging role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses | Marcus Maximilian Mücke | Received |
FRI-051 | Abnormalities in skin temperature and its 24-hour rhythm in patients with cirrhosis: sleep-wake and general clinical implications | Maria Garrido | Received |
SAT-051 | Erythropoietin treatment reduces inflammatory reaction and improves liver regeneration after major hepatic resection in cirrhotic rat models | Sukwon Suh | Received |
SAT-053 | The alternate renin angiotensin system is upregulated and Ang-(1-7) mediates vasodilatation in human cirrhosis | Stephen Casey | Received |
FRI-053 | Glutamine synthetase in endothelial cells of the blood-brain barrier: less but not insignificant? | Mariana M Oliveira | Received |
FRI-054 | Plasma lipid mediator (LM) profiling identifies hyper- and hypo-activated groups of patients with ACLF and targeted 20% human albumin solution infusion recalibrates abnormalities | Louise China | Received |
SAT-054 | PTTG1/DLK1, a new signaling pathway involved in the pathogenesis of liver fibrosis | Silvia Carvajal | Received |
THU-054 | TGR5 plays a protective role against portal hypertension in LCA induced liver damage in mice | Caroline Klindt | Received |
SAT-055 | Decreased levels of crucial complement pathway components in patients with advanced liver cirrhosis | Signe Glargaard | Received |
FRI-055 | Albumin binding capacity is impaired in decompensated liver cirrhosis and dysfunction is reversed by targeted in vivo 20% human albumin solution infusions | Louise China | Received |
THU-055 | Minimal hepatic encephalopathy is associated with increased capacity to eliminate superoxide and peroxynitrite in lymphocytes | Carmina Montoliu | Received |
FRI-056 | Survival predictors in cirrhotic patients with refractory ascites treated with transjugular intrahepatic portosystemic shunt | Marta Aicart-Ramos | Received |
SAT-056 | Collapsed reticular network during the initiation and progression of hepatic fibrosis in rat and human livers | Shi-Lei Wen | Received |
THU-056 | Extracellular matrix turnover is regulated in 3D disease-specific human liver scaffolds engineered with human hepatic stellate cells | Diana Julie Leeming | Received |
THU-057 | Low sensitivity to thrombomodulin in patients with cirrhosis; Impact of factor VIII increase and protein C deficiency | Armand Abergel | Received |
SAT-057 | Toll-like receptor polymorphisms compromise the inflammatory response against translocated bacterial antigens in cirrhosis | Paula Piñero Romero | Received |
FRI-057 | Intestinal inflammation worsens epithelial barrier function in rats with cirrhosis and ascites: role of commensal gut flora | Agustín Albillos | Received |
FRI-058 | Cannabinoid receptor 1 mediates M1 polarization of bone marrow-derived monocytes/macrophages via RhoA/NF-?B p65 and ERK1/2 signaling pathways respectively in mouse fibrotic liver | Le Yang | Received |
SAT-058 | Thyroid Hormone receptor regulates hepatic stellate cell activation | Paul P. Manka | Received |
THU-058 | Genetic determinants influencing on overt hepatic encephalopathy and acute-on-chronic liver failure | Antonio Gil-Gómez | Received |
THU-059 | Impaired cerebral oxygenation, but preserved cerebrovascular reactivity, in an animal model of hepatic encephalopathy | Anna Hadjihambi | Received |
SAT-059 | B. pseudocatenulatum CECT7765 effect on intestinal microbiota of rats with bile duct ligation | Oriol Juanola Juárez | Received |
FRI-059 | Beneficial effects of octrotide on intrahepatic angiogenesis via somatostatin receptor 2 in portal hypertensive and cirrhotic rats | Jinhang Gao | Received |
SAT-060 | Treatment with anti-TNFa reduces neuroinflammation and restores neurotransmission, learning and motor coordination in rats with hepatic encephalopathy | Vicente Felipo | Received |
THU-060 | Brain glymphatic clearance is impaired in a rat model of cirrhosis | Anna Hadjihambi | Received |
THU-061 | Progression of cirrhotic liver disease towards acute-on-chronic liver failure triggers changes in innate immune cell phenotype and their response to pro-inflammatory stimuli | Alexander AN Maini | Received |
SAT-062 | New animal model of obesity and chronic liver disease to provide insights on non-alcoholic liver disease-induced hepatic encephalopathy | Ochoa-Sanchez Rafael | Received |
FRI-062 | Functional cortical connectivity is disturbed in patients with cirrhosis even when neuropsychometric performance is unimpaired | Harry D Zacharias | Received |
THU-062 | Extracellular vesicles induce renal tubular cells apoptosis, oxidative stress and functional abnormalities in patients with an acute decompensation of cirrhosis | Alessandra Brocca | Received |
FRI-063 | Inhibition of macrophage infiltrations by thalidomide improves muscle wasting of cirrhotic rats | Han-Chieh Lin | Received |
SAT-063 | Impact of von Willebrand factor/ADAMTS-13 on the pro-coagulant imbalance detected in cirrhosis | Vincenzo La Mura | Received |
THU-063 | A novel population of immunosuppressive CD8 T cells is expanded in patients with decompensated liver disease | Fanny Lebosse | Received |
THU-064 | Simvastatin neither reduces gut bacterial translocation nor sistemic/mesenteric inflammation in cirrhotic rats with ascites | Agustín Albillos | Received |
SAT-064 | Effects of melatonin in hepatopulmonary syndrome induced biliar duct ligation in rats | Norma Possa Marroni | Received |
SAT-065 | Protective effect of melatonin on carbon tetrachloride-induced chronic hepatotoxicity | Norma Possa Marroni | Received |
THU-065 | Osteoprotegerin production and profibrotic activity in liver fibrosis are TGFß dependent | Adhyatmika Adhyatmika | Received |
FRI-065 | Activation of proinflammatory citokines is involved in muscle wasting in mice model of carbon tetrachloride induced liver cirrhosis | Michela Giusto | Received |
FRI-066 | Vascular morphology alterations during liver cirrhogenesis in rats | Geert Peeters | Received |
THU-066 | Osteoprotegerin is more than a serum marker in liver fibrosis | Adhyatmika Adhyatmika | Received |
SAT-067 | Regulation of the NLRP3 inflammasome in monocytes and macrophages from patients with decompensated cirrhosis by low-dose genotoxic stress | Nilay Koese | Received |
FRI-067 | Impact of sustained virological response to interferon therapy for chronic hepatitis C on recurrence and long-term survival in patients with hepatocellular carcinoma | Hiroji Shinkawa | Received |
SAT-068 | Elevated levels of circulating osteopontin in patients with cholangiocarcinoma predict poor survival after tumor resection | Sven H. Loosen | Received |
THU-068 | Trunk and branch drivers in hepatocellular carcinoma: impact of molecular heterogeneity | Agrin Moeini | Received |
SAT-069 | Pathomolecular scoring and diagnostic algorithm of atypical hepatocellular adenomas: a clue for malignant transformation | Valérie Paradis | Received |
THU-069 | The systemic inflammatory response is a prognostic marker in human immunodeficiency virus-infected patients with hepatocellular carcinoma | David James Pinato | Received |
FRI-070 | Development of de novo and recurrent hepatocellular carcinoma in a Romanian cohort of compensated HCV genotype 1b liver cirrhosis with SVR after 3D and ribavirin therapy | Liana Gheorghe | Received |
SAT-070 | Serum Wisteria Floribunda agglutinin-positive sialylated mucin 1 as a biomarker of hepatic progenitor cell/biliary features in hepatocellular carcinoma and of recurrence after curative therapy | Nobuharu Tamaki | Received |
THU-070 | Rising incidence of hepatocellular carcinoma in a Spanish health area between 2008 and 2016 | Alberto Lue´ | Received |
THU-071 | Laparoscopic ablation for hepatocellular carcinoma: proposal of a 6-months mortality score for patient selection based on more than 1000 procedures | Alessandro Vitale | Received |
SAT-071 | ASS1 immunohistochemistry identifies unclassified hepatocellular adenoma. Experience of a single French liver center | Paulette Bioulac-Sage | Received |
FRI-071 | Development of risk prediction model for hepatocellular carcinoma progression of indeterminate nodules in hepatitis B virus-related cirrhotic liver | Hyo Jung Cho | Received |
SAT-072 | Higher rates of cirrhosis, decompensation, and hepatocellular carcinoma (HCC) in Asian and Hispanic patients with Hepatitis C (HCV) Infection compared to White and Black ethnicity regardless of gender differences: a single center study in the U.S. | Pauline Nguyen | Received |
THU-072 | Pancreatic insufficiency related to hepatocellular carcinoma treatment: early detection and treatment improves therapeutic adherence | Alvaro Diaz-Gonzalez | Received |
THU-073 | Mipsagargin, a PSMA-directed prodrug, provides clinical benefit in patients with advanced sorafenib-refractory hepatocellular carcinoma | Devalingam Mahalingam | Received |
SAT-073 | The prognosis of single large hepatocellular carcinoma was distinct from the BCLC stage A or B | Pei-Chang Lee | Received |
FRI-074 | Determinants of long term survival and recurrence patterns after radiofrequency ablation for hepatocellular carcinoma developed on cirrhosis | Manon Allaire | Received |
SAT-074 | Validation of novel eligibility criteria by integrating ALBI grade and progression pattern for sorafenib-failed hepatocellular carcinoma | Pei-Chang Lee | Received |
FRI-075 | Conditional probability of long-term survival in patients with locally advanced and metastatic hilar cholangiocarcinoma | Marcia Gaspersz | Received |
SAT-075 | The long-term outcomes of patients with the Barcelona Clinic Liver Cancer stage 0 hepatocellular carcinoma after radiofrequency ablation therapy | Pei-Chang Lee | Received |
THU-075 | Albumin-Bilirubin grade based novel risk prediction model for patients with hepatocellular carcinoma undergoing chemoembolization | Dong Hyun Sinn | Received |
THU-076 | CEUS LI-RADS are effective in predicting the risk hepatocellular carcinoma of liver nodules | Fabio Piscaglia | Received |
SAT-076 | Polymorphisms in the cyclooxygenase-2 (COX-2) gene, vascular endothelial growth factor (VEGF) and methylenetetrahydrofolate reductase (MTHFR) gene in patients with hepatocellular carcinoma and hepatitis C virus infection | Sylene Coutinho Rampche de Carvalho | Received |
FRI-076 | The prognostic value of hepatic artery and portal vein involvement in patients with perihilar cholangiocarcinoma | Marcia Gaspersz | Received |
FRI-077 | Black hepatocellular carcinoma patients diagnosed after 2010 have worse long-term survival than white patients | Jacqueline Estevez | Received |
SAT-077 | Relationship between overall survival and time to progression after transarterial chemoembolization therapy in patients with hepatocellular carcinoma | Tadaaki Arizumi | Received |
THU-077 | Prospective validation of a score to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis that takes into account sustained virological response. Influence of direct-acting antivirals | Andres Castaño | Received |
SAT-078 | Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study | Philip Broadhurst | Received |
FRI-078 | Temporary suspension of sorafenib by adverse effects is associated with longer survival in patients with hepatocellular carcinoma | Maria Varela | Received |
FRI-079 | Functional health literacy can affect patient perception for the need for liver imaging for HCC screening | Jasmohan Singh Bajaj | Received |
SAT-079 | Serum biomarker (´GALAD´) response after resection of hepatocellular carcinoma: impact of tumour recurrence | Philip J Johnson | Received |
THU-079 | Advanced BCLC hepatocellular carcinoma includes a very heterogeneous patient population treatable with different therapies and with different prognosis | Francesca Garuti | Received |
THU-080 | Serum microRNAs as biomarkers for cirrhosis and hepatocellular carcinoma in Hepatitis C | Anna Weis | Received |
SAT-080 | Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a european multicentric study | Philippe Kolly | Received |
FRI-080 | Telomerase activity: a valuable marker of hepatocelluar carcinoma development in cirrhotic hepatitis C patients | Nihal Mohamed El-Habachi | Received |
FRI-081 | Identification of actionable mutations in circulating cell-free tumour DNA as a prognostic biomarker in hepatocellular carcinoma | Jessica Howell | Received |
THU-081 | Interferon-free therapy of chronic hepatitis C does not change the short-term risk for de novo hepatocellular carcinomas in patients with liver cirrhosis | Friederike Mettke | Received |
THU-082 | Resection of larger hepatocellular adenomas: when is it justified? | Anne Julia Klompenhouwer | Received |
FRI-082 | The risk of hepatitis B virus reactivation is considerably high during sorafenib therapy in patients with advanced hepatocellular carcinoma | Ji Hye Seo | Received |
SAT-082 | The diagnostic and prognostic values of serum PIVKA-II in Thai patients with hepatitis B-related hepatocellular carcinoma | Pisit Tangkijvanich | Received |
SAT-083 | Adjuvant Huaier granule for hepatocellular carcinoma after curative resection: A phase IV, multicenter, randomized, and parallel-group controlled clinical trial | Qian Chen | Received |
FRI-083 | Prognostic significance of co-expression of programmed cell death 1 and its ligand 1 in resectable hepatocellular carcinoma | Jihyun An | Received |
FRI-084 | Combined Effect of Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and Programmed Cell Death 1 Ligand 1 (PD-L1) expression in tumor infiltrating lymphocytes on prognostic outcomes after resection of hepatocellular carcinoma | Jihyun An | Received |
SAT-084 | Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy | Ramy Ibrahim Kamal Jouness | Received |
THU-084 | Predictors for successful downstaging in patients with BCLC intermediate stage hepatocellular carcinoma | Annelotte Broekhoven | Received |
FRI-085 | Neuroligin4 over expression on natural killer cells cause their impairment in patients with cirrhosis and hepatocellular carcinoma | Johnny Amer | Received |
THU-085 | Risk of hepatocellular carcinoma development in patients with cirrhosis of viral etiology assessed by protein induced by vitamin k absence or antagonist II | Gian Paolo Caviglia | Received |
SAT-085 | Significantly lower rates of cirrhosis and worse long-term survival in cryptogenic hepatocellular carcinoma compared to viral etiologies: results of a multi-center international cohort | Tomi Jun | Received |
THU-086 | The role of spleen stiffness measurement as predictor of hepatocellular carcinoma recurrence after curative resection in cirrhotic patients | Giovanni Marasco | Received |
SAT-086 | The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without pegylated interferon: a Belgian experience | Rob Bielen | Received |
FRI-086 | Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma | Martha M Kirstein | Received |
THU-087 | Portal vein infiltration in patients with hepatocellular carcinoma: the impact of correct classification | Arndt Weinmann | Received |
SAT-087 | Significance of serum exosomal miR-122 and miR-21 as a predictive biomarker in hepatocellular carcinoma patients who underwent transarterial chemoembolization | Tomoyuki Suehiro | Received |
SAT-088 | Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma | Rocco Granata | Received |
THU-088 | Management of people with early or very early stage hepatocellular carcinoma: an attempted network meta-analysis | Avik Majumdar | Received |
SAT-089 | A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin | Torsten Voigtländer | Received |
FRI-089 | Safety and efficacy of chemosaturation in patients with primary and secondary liver tumours: a single-centre experience after 54 treatments | Martha M Kirstein | Received |
THU-089 | The effect of antiviral treatment on hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma | Gab Jin Cheon | Received |
SAT-090 | Extent of portal invasion in patients with hepatocellular carcinoma: the more, the worse? | Roman Kloeckner | Received |
THU-090 | Operability of perihilar cholangiocellular carcinoma can be reliably predicted by combination of endoscopic retrograde cholangiography, endoscopic ultrasound and computer tomography as variables in the European staging system | Bernhard Schlevogt | Received |
FRI-090 | Improved prediction of survival by a risk factor-integrated inflammatory score in Sorafenib treated hepatocellular carcinoma | Martin Franz Sprinzl | Received |
SAT-091 | Soluble Axl identifies patients at higher risk for hepatocellular carcinoma development: results from a large scale multicenter analysis | Wolfgang Mikulits | Received |
FRI-091 | Novel circulating cell free DNA methylation alterations as a biomarker for the detection of hepatocellular carcinoma | Ju Dong Yang | Received |
THU-092 | Alpha-fetoprotein levels before and after sustained virological response with direct- acting antivirals in patients with liver cirrhosis due to hepatitis C virus | Carmen Alvarez-Navascues | Received |
FRI-092 | Validation of the ALBI grade as a substitute for the Child-Pugh class in the BCLC classification of hepatocellular carcinoma and of the additional value provided by the Neutrophil-to-Lymphocyte Ratio | Matteo Colombo | Received |
SAT-092 | Circulating tumour-associated microparticles in liver cancer: a question of tumour diameter and volume? | Sabine Katharina Urban | Received |
SAT-093 | Characteristics of conversion to 2nd line treatment in sorafenib-treated advanced hepatocellular carcinoma patients | Sadahisa Ogasawara | Received |
FRI-093 | The optimal cutoff value of serum alpha-fetoprotein in the diagnosis of hepatocellular carcinoma | Jung-Fa Tsai | Received |
FRI-094 | External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study | Mauro Borzio | Received |
SAT-094 | Impact of survival after moving onto the end-of-life care in patients with hepatocellular carcinoma | Sadahisa Ogasawara | Received |
SAT-095 | The expression of SALL4 and its clinical significance in hepatocellular carcinoma | Xiaoyu Wen | Received |
THU-095 | Clinical features of hepatocellular carcinoma in the elderly in a hepatitis B endemic country - a comparative study of 1430 cases | Chang-Chuen Mark Cheah | Received |
FRI-095 | Previous and resolved hepatitis B virus infection is not a risk factor for the development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus or alcohol | Carlos Rodríguez-Escaja | Received |
SAT-096 | Sorafenib therapy in orthotopic liver transplant recipients with hepatocellular carcinoma beyond Milan criteria on explant | Sanjaya Kumar Satapathy | Received |
THU-096 | Risk of hepatocellular carcinoma recurrence in hepatitis C cirrhotic patients treated with direct acting antivirals | Giuseppe Cabibbo | Received |
FRI-096 | Short-Course carbon-ion radiation therapy for hepatocellular carcinoma: a nationwide survey by Japan Carbon Ion Radiation Oncology Study Group (J-CROS 1504) | Kei Shibuya | Received |
FRI-097 | Treatment patterns and clinical outcomes for patients with hepatocellular carcinoma from China: a sub-analysis of the Global Hepatocellular Carcinoma BRIDGE Study | Minshan Chen | Received |
SAT-097 | Serial changes in serum biomarkers (GALAD model) prior to detection of HCC by ultrasound surveillance; application of statistical process control methodology | Sarah Berhane | Received |
THU-097 | Hepatocellular carcinoma and rheumatoid arthritis: a 10-year population-based propensity-score matched cohort study in Taiwan | Ching-Sheng Hsu | Received |
SAT-098 | Clinicopathological characteristics of Intrahepatic sarcomatoid cholangiocarcinoma: 11 cases in single center experience | Yang-Hyon Baek | Received |
FRI-098 | Phase I dose escalating study of hypoxia-activating agent tirapazamine in combination with trans-arterial embolization in patients with intermediate stage hepatocellular carcinoma | Nadine Abi-Jaoudeh | Received |
THU-098 | Transarterial chemoembolizaton combined with sorafenib for intermediate-stage hepatocellular carcinoma: a window of tumor burden for survival benefit | Guohong Han | Received |
THU-099 | The malignant transformation of hepatocellular adenoma: experience of a French liver center | Christine Sempoux | Received |
FRI-099 | PET/CT findings using 18F-labeled galactose tracer (FDGal) vs. 18F-labeled glucose tracer (FDG) in patients with hepatocellular carcinoma | Kirstine Petrea Bak-Fredslund | Received |
SAT-099 | Utility of serum alpha-fetoprotein measurement with a cutoff of 20ng/mL in addition to ultrasound surveillance for hepatocellular carcinoma in patients with chronic hepatitis B - a regression discontinuity analysis | Yan-Zheng Daniel Lim | Received |
FRI-100 | EpCAM-positive circulating tumor cells as liquid biomarker for early micrometastases and HCC recurrence risk | Kornelius Schulze | Received |
THU-100 | Radiological assessments in patients with hepatocellular carcinoma following transarterial chemoembolization: can initial response independently predict the survival regardless of tumor load? | Guohong Han | Received |
THU-101 | Hepatocellular carcinoma diagnostic performance of liver imaging reporting and data system for contrast enhanced ultrasound and of quantitative contrast enhanced ultrasound | Cosmin Gabriel Cristea | Received |
FRI-101 | Analysis of the breath metabolome in patients with Hepatocellular carcinoma | Ghassoub Rifai | Received |
SAT-101 | Plasma micoRNA-21, 26a, and 29a-3p as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma | Soon Sun Kim | Received |
SAT-102 | A low incidence of hepatocellular carcinoma in patients with genotype 1b compensated cirrhosis treated with paritaprevir/ritonavir, ombitasvir and dasabuvir ± ribavirin in a tertiary center: a matter of better selection? | Stefan Chiriac | Received |
THU-102 | Plasma microvesicles levels can predict the development of hepatocellular carcinoma in patients with cirrhosis | Cristina Levi | Received |
FRI-102 | Regional differences in the presentation and management of patients with hepatocellular carcinoma by liver disease etiology | Ming-Lung Yu | Received |
THU-103 | Hand-foot-skin reaction of grade two or higher within sixty days as the best response criterion for survival prediction in hepatocellular carcinoma treated by sorafenib | Guohong Han | Received |
FRI-103 | Temporal trends in etiology of liver disease, tumor characteristics, and long-term survival of patients with hepatocellular carcinoma: results of a single-center U.S. cohort from 1997-2016 | Pauline Nguyen | Received |
SAT-103 | Analysis of postprogression survival of patients with advanced hepatocellular carcinoma treated with sorafenib | Yoshiyuki Wada | Received |
FRI-104 | Activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis | Lei Ling | Received |
SAT-104 | Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience | Stefano Okolicsanyi | Received |
THU-104 | Close association of arrest-defective protein 1 (ARD1) overexpression with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma | Danbi Lee | Received |
SAT-105 | Hepatocellular carcinoma in elderly patients referred to a tertiary center with multidisciplinary team approach: clinical presentation and outcomes | Stefano Okolicsanyi | Received |
SAT-106 | Early changes in perfusion-computed tomography scan parameters as a marker of improved outcomes in patients with hepatocellular carcinoma treated with Sorafenib | Stefano Okolicsanyi | Received |
FRI-106 | Effect of novel AKT inhibitor ARQ 751 as single agent and its combination with sorafenib on hepatocellular carcinoma in a cirrhotic rat model | Kurma Keerthi | Received |
FRI-107 | Kangai 1 C-terminal interacting tetraspanin plays an important role in cholangiocarcinogenesis | Khac Cuong Bui | Received |
THU-107 | Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study | David James Pinato | Received |
FRI-108 | RNA sequencing of intrahepatic cholangiocarcinoma reveals two prognostic subclasses | Keun Soo Ahn | Received |
SAT-108 | Serum hepatocyte growth factor (HGF) is a potential marker for baseline liver function and its early deterioration in patients treated with sorafenib | Yutaka Yasui | Received |
THU-108 | CRIPTO expression in hepatocellular carcinoma | Danny van der Helm | Received |
SAT-109 | Identification of tumour suppressive and oncogenic microRNAs in gallbladder carcinoma | Stephanie Roessler | Received |
FRI-109 | PNPLA3 p.I148M risk allele carriers might be at-risk of chemotherapy- associated steatohepatitis (CASH) | Marcin Krawczyk | Received |
THU-109 | Intra-tumour heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma | David James Pinato | Received |
FRI-110 | Targeting tumour-stromal interactions – differential pharmacological modification of AMPK/mTORC1 in human hepatic stellate cells and hepatocellular carcinoma | Katrin Schölzel | Received |
SAT-110 | Kupffer cells as antigen-presenting cells in mouse livers with hepatocellular carcinoma | Stephanie Lacotte | Received |
SAT-111 | Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1alpha-related release of VEGF-A | Stefania Cannito | Received |
FRI-111 | IMPDH exerts a tumor-suppressing role in hepatocellular carcinoma | Kan Chen | Received |
THU-111 | DPP4 inhibition reveals interleukin-33–dependent eosinophil-mediated tumor immunity in hepatocellular carcinoma | Clémence Hollande | Received |
FRI-112 | Hepatocyte nanodelivery using siRNA c-Jun N-terminal Kinase-2 (siJnk2) for the treatment of chronic liver disease | Marius Maximilian Woitok | Received |
SAT-113 | Impact of natural killer cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients | Simona Onali | Received |
THU-113 | Role of RAS-dependent signaling pathways in hepatic carcinogenesis | Christian Lechler | Received |
FRI-113 | Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification | Julien Calderaro | Received |
THU-114 | Hepatic tumour burden is reduced by endogenous overexpression of chemerin-157 | Elisabeth Margareta Haberl | Received |
SAT-115 | Fatty liver binding protein 4: a targetable adipokine in hepatocellular carcinoma related to metabolic syndrome | Samira Laouirem | Received |
THU-115 | Preclinical evaluation of polyethylenimine-mediated RNA interference of Polo-Like Kinase 1 gene for ultrasound image-guided treatment of hepatocellular carcinoma | Eric Robinet | Received |
FRI-115 | Genetic and epigenetic bases of the relationship between reduced OCT1 expression and poor response to sorafenib in hepatocellular carcinoma and cholangiocarcinoma | Jose J.G. Marin | Received |
FRI-116 | IL6-dependent genomic instability Heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis | Jonathan H. Axelrod | Received |
SAT-116 | Metformin reduces cell migration and down-regulates epithelial to mesenchymal transition by AMPK / Foxo3a pathway in human intrahepatic cholangiocarcinoma | Sabina Di Matteo | Received |
THU-116 | Inhibition of lymph node metastasis by CTGF in Notch1 driven malignant transformation of rat liver oval cells | Chao Liu | Received |
SAT-117 | Molecular basis of natural killer cell dysfunction in hepatocellular carcinoma | Gabriele Missale | Received |
FRI-117 | Insulin/IGF-1 receptors mediate acquired resistance to anti-EGFR therapy in human cholangiocarcinoma cells | Javier Vaquero | Received |
THU-117 | Tumour suppressor SH2D4A is involved in endosomal trafficking of STAT3 in hepatocellular carcinoma cells | Carolin Ploeger | Received |
FRI-118 | Chromosomal aberrations are effected by transformation-related protein 53 deletion in inflammation induced hepatocarcinogenesis | Michael Svinarenko | Received |
THU-118 | Genetic differences in hepatocellular carcinoma among chronic persistent hepatitis B virus infection with or without viral suppression and prior hepatitis B virus infection | Fukiko Kawai-Kitahata | Received |
SAT-118 | DNA circulating free in patients with hepatocellular carcinoma | Valérie Dejour | Received |
THU-119 | Functional role of CCL5/RANTES for hepatocellular carcinoma progression during chronic liver disease | Antje Mohs | Received |
FRI-119 | Free fatty acids enhance CD36 knockdown in primary human hepatocytes and abrogate PTEN expression – recapitulation of NASH-associated HCC | Jan-Peter Sowa | Received |
SAT-119 | Fractalkine-CX3CR1 is the only predictor for mortality in hepatocellular carcinoma patients treated with curative radiofrequency ablation | Wei Teng | Received |
FRI-120 | Extracellular ATP and subsequent purinergic P2Y2 receptor signalling promote liver tumorigenesis in mice | Isabel Schulien | Received |
THU-120 | miR-22 deficiency fosters hepatic tumour development | Anne-Sophie Ay-Berthomieu | Received |
SAT-120 | Exome sequencing identifies a mutation associated with hepatocellular carcinoma development in hepatitis C virus infected individuals | Rodrigo Feliciano Carmo | Received |
THU-121 | Proteomic analysis identifies argininosuccinate synthase 1 as a useful biomarker for hepatocellular adenoma classification and patient management | Anne-Aurelie Raymond | Received |
FRI-121 | Rapamycin and zoledronic acid synergistically repolarize tumour associated macrophages towards anti-HCC responses | Misbah Aslam | Received |
SAT-121 | Identification of invasion-addicted genes driven by transforming growth factor-beta in hepatocellular carcinoma | Wolfgang Mikulits | Received |
SAT-122 | Integrated analysis of exosomal microRNA, gene, and pathway regulatory networks in fibrosis and hepatocarcinogenesis | Robert Cheng | Received |
THU-122 | RIPK1 suppresses a TRAF2-dependent pathway to liver cancer | Tom Luedde | Received |
SAT-123 | Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers | Richard Bethell | Received |
FRI-123 | Molecular characterization of the immune class of hepatocellular carcinoma | Iris Martinez-Quetglas | Received |
THU-123 | A small number of senescent hepatocytes is sufficient to attenuate liver regeneration and enhance tumorigenesis | Anna Potapova | Received |
THU-124 | Cerium oxide nanoparticles display anti-tumoral activity and improve survival in experimental hepatocellular carcinoma | Guillermo Fernandez-Varo | Received |
FRI-124 | TGF-ß oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response | Iris Martinez Quetglas | Received |
SAT-124 | VEPH1 regulates the occurrence and development of hepatocellular carcinoma by affecting the PI3K/Akt/mTOR signal pathway | Pinging Dong | Received |
FRI-125 | Characterization of cancer associated fibroblasts in primary site and metaststic lymph nodes of intrahepatic cholangiocarcinoma by immunohistochmistry | Naoki Uyama | Received |
THU-125 | The absence of OCT1 at the plasma membrane of tumor cells is associated with a worse response of hepatocellular carcinoma to sorafenib | Johannes Weiss | Received |
THU-126 | A new in vitro hepatocellular carcinoma model based on human normal and fibrotic 3D extracellular matrix scaffold bio-engineering | Andrea Telese | Received |
FRI-126 | Selenoenzyme glutathione peroxidase 4 affects profile of infiltrating immune cell in hepatocellular carcinoma | Nataliya Rohr-Udilova | Received |
SAT-126 | CCL2-dependent monocyte recruitment contributes to a tumor-promoting microenvironment in a combined fibrosis-HCC model | Peter Leonard Schrammen | Received |
SAT-127 | CCAAT/Enhancer Binding Protein Delta exerts tumor-supportive effects but is down-regulated in patient hepatocellular carcinoma | Pengyu Liu | Received |
FRI-127 | Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib | Hyo Jung Cho | Received |
THU-127 | microRNA-34a and natural killer cells: an immuno-epigenetic approach to halt hepatocellular carcinoma progression | Amira Khaled Abdelhamid | Received |
THU-128 | The anti-inflammatory receptor TREM-2 protects the liver from hepatocellular carcinoma development | Aitor Esparza-Baquer | Received |
FRI-128 | Overexpression of arrest-defective protein 1 in dysplastic hepatic nodule as a possible marker of malignant potential | Hyo Jeong Kang | Received |
FRI-129 | Liver microRNA hsa-miR-125a-5p may exert an oncosuppressor effect on HCC | Nicola Coppola | Received |
SAT-129 | Distinct features of early and late-stage liver cancer cells correlate with their response to metabolic perturbation | Zeribe Nwosu | Received |
THU-129 | Chronic treatment with over-the-counter H1 or H2 histamine receptor blockers decreases cholangiocarcinoma xenograft tumor growth, angiogenesis and EMT | Heather Francis | Received |
THU-130 | Effect of hepatitis E virus infection on the human hepatic innate immune response in human liver chimeric mice | Ibrahim M. Sayed | Received |
FRI-130 | Prevalence and risk factors for hepatitis B infection in the adult population of Georgia: a nationwide survey | Ana Kasradze | Received |
FRI-131 | Interferon-free antiviral therapy does not increase the risk of developing short term hepatocellular carcinoma in patients with cirrhosis infected with hepatitis C virus | Andrea Nuñez | Received |
SAT-131 | AKT inhibitor ARQ 092 and sorafenib additively inhibit progression of hepatocellular carcinoma and improve immune system in cirrhotic rat model | Zuzana Macek Jilkova | Received |
FRI-132 | Prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders | Anna Parfieniuk-Kowerda | Received |
THU-132 | Common polymorphisms in the TLR3 gene are stronger associated with spontaneous clearance of Hepatitis B virus infection in caucasians than variants of the HLA gene | Janett Fischer | Received |
THU-133 | Identification of serum metabolite profiles associated with the risk of developing hepatitis B-related hepatocellular carcinoma using metabolomics | Jia-Kai Hsu | Received |
FRI-133 | In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir? | Arianna Battisti | Received |
SAT-133 | Incidence and mortality of viral hepatitis in China | Mingyuan Zhang | Received |
FRI-134 | Mother-to-child transmission of hepatitis B virus in Ethiopia | Asgeir Johannessen | Received |
THU-134 | Serum hepatitis B core antibody as a novel tool to assess hepatic inflammation guide antiviral decision-making in chronic hepatitis B patients with normal alanine aminotransferase levels | Jiyuan Zhou | Received |
SAT-134 | Re-evaluation of chronic hepatitis B patients lost to follow-up: results from the northern holland retrieval project | Nina Beekmans | Received |
THU-135 | Progesterone receptor mutations predisposes to HEV infection in the HIV-positive host | Jose Daniel Debes | Received |
FRI-135 | Clinical outcomes were comparable between chronic hepatitis B patients with virological response using oral antiviral therapy and inactive carriers when adjusting for fibrotic burden | Beom Kyung Kim | Received |
SAT-136 | Noninvasive models to predict liver fibrosis in patients with chronic hepatitis B: a study from Turkey | Pinar Korkmaz | Received |
THU-136 | Correlation of hepatitis B virus genomic variants with HBsAg Titers and HBV-DNA levels in a large European study cohort of patients with chronic hepatitis B | Kai-Henrik Peiffer | Received |
SAT-137 | Clinical significance of post-liver transplant hepatitis E seropositivity in high prevalence area of genotype 3: interim result of 8-month prospective follow-up study | Piyawat Komolmit | Received |
FRI-137 | Association between mutations on the basal core promoter region and hepatocellular carcinoma in Vietnamese chronic hepatitis B patients | Cam Huong Thi Nguyen | Received |
THU-138 | Impact of chronic liver disease on the survival of patients hospitalized with acute hepatitis A infection: nationwide hospital admission data from Thailand | Kittiyod Poovorawan | Received |
SAT-138 | A five-year single centre experience of hepatitis E virus infection during pregnancy from New Delhi | Premashis Kar | Received |
FRI-138 | 2´-C-methylcytidine inhibits hepatitis E virus replication but antagonizing ribavirin | Changbo Qu | Received |
SAT-139 | The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification | Lorenzo Piermatteo | Received |
THU-139 | A nationwide seroprevalence of hepatitis a in Republic of Korea from 2005 to 2014, before and after peak outbreak in 2009 | Sook-Hyang Jeong | Received |
FRI-139 | Phenotypic and genotypic shifts of hepatitis B virus in treatment naïve patients following extensive use of antivirals in a chronic hepatitis B endemic area | Chau-Ting Yeh | Received |
SAT-140 | Poor adherence to hepatitis B screening protocols prior to rituximab; a multicentre South Australian study | Alan Wigg | Received |
FRI-140 | Identificaiton of an hot integration area for hepatitis B viral genome in the tenth intron of DEP Domain-Containing 5 gene in hepatoma patients with unfavorable postoperative prognosis | Chau-Ting Yeh | Received |
THU-140 | Hepatitis E virus infection and ribavirin treatment in patients with chronic lymphocytic leukemia receiving ibrutinib | Laurent Alric | Received |
THU-141 | The pro-inflammatory CD161+CD4+ T cells were recruited to liver through C-X-C motif chemokine receptor 6 (CXCR6)-C-X-C motif chemokine ligand 16 (CXCL16) and CX3CR1-CX3CL1 axes during chronic hepatitis B | Li-Sha Cheng | Received |
FRI-141 | Increased natural killer cell function after structured interruption of long-term nucleos(t)ide analogue therapy is associated with active hepatitis | Christine Lea Zimmer | Received |
SAT-141 | A territory-wide study on the seroprevalence of hepatitis B and C virus in the general population in Hong Kong, China | Sze Hang Kevin Liu | Received |
THU-142 | Hepatitis Delta Antigen (HDAg) is characterized by an extensive degree of genetic variability that correlates with elevated levels of serum HDV-RNA | Luna Colagrossi | Received |
THU-143 | Nucleos(t)ide analogue decreased liver stiffness of e-antigen negative chronic hepatitis B (CHB) patients over a 10-year interval | Lung-Yi Mak | Received |
FRI-143 | Characterization and evaluation of hepatic fibrosis degree in patients with chronic hepatitis B virus infection with normal transaminases | Cristina San Juan | Received |
SAT-143 | Identifying true inactive HBV carriers using fibrosis-4 index | Tai-Chung Tseng | Received |
THU-144 | Absence of hepatitis B reactivation among veterans with serological evidence of previous hepatitis B infection receiving anti-hepatitis C direct acting antivirals | Lydia Tang | Received |
SAT-144 | Anti-HEV seroprevalence rate in the Americas | Thomas Horvatits | Received |
FRI-144 | Frequent delayed hepatitis B surface antigen spontaneous clearance among high risk groups | Daniela K van Santen | Received |
FRI-145 | The value of subtyping genotype A in chronic hepatitis B: differences in disease course and implications for therapy | Enoka Gonsalkorala | Received |
SAT-145 | Further evaluation of the RoboGene Kit for HDV RNA quantification including viral load monitoring under therapy and performance in different genotypes | Ute Hofmann | Received |
THU-145 | Prevalence, determinants of chronic hepatitis B infection and hepatitis B genotypes in multi-ethnic Suriname | M. Sigrid. Mac Donald - Ottevanger | Received |
THU-146 | hepatitis C virus hepatitis B virus co-Infection disproportionately worsens cirrhosis, hepatic decompensation, and hepatocellular carcinoma incidence in Non-Asians as compared to Asians | Pauline Nguyen | Received |
SAT-146 | Gain of positively charged amino acids at specific positions of HBsAg C-terminus tightly correlates with HBV-induced hepatocellular carcinoma by altering the structural folding of this domain | Valentina Svicher | Received |
FRI-146 | Liver transient elastography (Fibroscan©): performance for the absolute mortality and clinical disease progression risk evaluation in chronic hepatitis C | Fatima Serejo | Received |
SAT-147 | Potential implications of detecting Hepatitis B surface antigen in asymptomatic people in an endemic community through medical camps | Varun Gupta | Received |
THU-148 | Transient elastography evolution in non treated patients with chronic hepatitis B (CHB) infection | Maria Luisa González-Diéguez | Received |
SAT-148 | Hepatitis E virus activates signal transducer and activator of transcription 3 to facilitate viral replication | Wenshi Wang | Received |
THU-149 | Clinical and virological outcomes of hepatitis B virus inactive carriers and gray zone patients: a comparative analysis using current EASL and AASLD Guidelines criteria | Martin Sebastian Bonacci | Received |
SAT-149 | A revisit of anti-HBc IgM in the differentiation of acute HBV infection from chronic HBV infection with acute flare-up | Yi-Cheng Chen | Received |
SAT-150 | Development and validation of a simple score to select HBV-infected patients for antiviral therapy in Africa | Yusuke Shimakawa | Received |
FRI-150 | Tenofovir, entecariv and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B | Jung Gil Park | Received |
THU-150 | Liver histologic spectrum in hepatitis B virus patients co-infected with the human immunodeficiency virus | Mauricio Lisker-Melman | Received |
SAT-151 | Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS) | Zobair M Younossi | Received |
THU-151 | Validation of the PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir | Mi Na Kim | Received |
THU-152 | Outcome in chronic hepatitis delta: differences between African and non-African patients | Ivana Carey | Received |
SAT-152 | PD-1+ CD8+ T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B | Nina Le Bert | Received |
FRI-152 | No changes in the coding sequence for HBV core protein after 6 weeks of treatment of HBV infected humanized mice with NVR 3-778 | Angela LAM | Received |
THU-153 | Serum cholinesterase: A predictive biomarker of hepatic reserves in patients with chronic Hepatitis D | Z Abbas | Received |
THU-154 | Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection | Andrew Vaillant | Received |
FRI-154 | Characterization of the intrahepatic immune response of virally-suppressed chronic hepatitis B patients to treatment with the oral TLR7 agonist GS-9620 | Lauke Boeijen | Received |
SAT-154 | Characterization of hepatitis delta infection in Israel: prevalence and genotypes | Orna Mor | Received |
FRI-155 | An algorythm including quantitave HBsAg and HBcrAg is useful for discrimation between hepatitis B virus inactive carriers and patients with active chronic hepatitis B HBeAg negative | Mar Riveiro Barciela | Received |
THU-155 | Absence of mutations in the HBsAg "a" determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol | Andrew Vaillant | Received |
SAT-155 | A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B | Patricia Mendez | Received |
THU-156 | Post-entry antiviral effects of nucleic acid polymers against hepatitis B virus infection in vitro | Andrew Vaillant | Received |
SAT-156 | High rates of renal tubular damage in HBV monoinfected patients long-term treated with Tenofovir: a cross-sectional, single center, real-life study in 414 patients | Pietro Lampertico | Received |
SAT-157 | Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients | Pietro Lampertico | Received |
FRI-158 | Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection | Meifang Han | Received |
THU-158 | A novel mid-scale screening assay to identify compounds with anti-HDV activity | Bettina Buchmann | Received |
FRI-159 | Baseline serum WFA+-M2BP level is a strong predictor of response to pegylated interferon-a in HBeAg-positive chronic hepatitis B patients | Mingyu Zhu | Received |
SAT-159 | Kinetics of serum HBsAg and HBcrAg in predicting response to pegylated interferon-based therapy in patients with HBeAg-negative chronic hepatitis B | Pisit Tangkijvanich | Received |
FRI-160 | Next generation sequencing identifies baseline HBV mutants associated with treatment response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B | Natthaya Chuaypen | Received |
THU-160 | Prediction of hepatitis B virus reactivation in lymphoma patients with resolved hepatitis B virus infection who received rituximab-containing chemotherapy: the roles of antiHBc/antiHBs quantification | Chiun Hsu | Received |
FRI-161 | Quantification of serum hepatitis B core-related antigen to understanding the hepatitis B virus and hepatitis D virus chronic infection | Alicia Ruiz-Ripa | Received |
FRI-162 | PreS1/PreS2/S and precore/core mutations related with major risk of hepatocellular carcinoma in patients with "grey-zone" chronic hepatitis B | Ana Isabel Gil | Received |
THU-162 | On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB | Darren Wong | Received |
THU-163 | On-treatment ALT flares are associated with HBsAg loss in genotype A chronic hepatitis B-infected patients treated with nucleotide analogue therapy | Darren Wong | Received |
FRI-163 | Increased hepatitis B virus (HBV) specific IFN- ? and IL17A secretion by T cell subsets in HBV infected non transmitting mothers and their HBV negative new-borns: A Novel mechanism for prevention of HBV vertical transmission | Nirupma Trehanpati | Received |
SAT-164 | Addition of (pegylated) interferon to entecavir increases response in treatment naïve HBeAg-positive patients with chronic hepatitis B | Seng Liem | Received |
THU-164 | Superior suppression of hepatitis B virus DNA and antigen levels in a chimeric mouse model when BB-103, a DNA-directed RNA interference agent, is coupled with standard of care drugs | David Suhy | Received |
THU-165 | Sequential combination therapy with IFN, rhIL-2 and therapeutic vaccine enhanced HBsAg loss in entecavir-suppressed CHB patients (the Endeavor study): an interim analysis | Di Wu | Received |
SAT-165 | Sustained efficacy and surface antigen seroconversion in the woodchuck model of chronic hepatitis B with the selective toll-like receptor 8 agonist GS-9688 | Simon P. Fletcher | Received |
FRI-165 | A new HDV mouse model showing important features of human infection and identifying MAVS as a key player in IFN-ß induction | Carla Usai | Received |
FRI-166 | Hepatitis B virus quasispecies complexity is lower in hepatitis B virus–hepatitis D virus infection than in hepatitis B virus monoinfection | Cristina Godoy | Received |
SAT-166 | Three-year efficacy and safety of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic hepatitis B | So Young Kwon | Received |
THU-166 | Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B | Pietro Lampertico | Received |
SAT-167 | Antiviral efficacy of a novel hepatitis B virus expression inhibitor in combination with entecavir and wIFN-alpha in woodchucks model of chronic hepatitis B | Steffen Wildum | Received |
FRI-167 | Identification of hepatitis B X protein regions responsible for the regulation of HBV transcription via histone modification | Danny Ka Ho Wong | Received |
FRI-168 | Proteomic profiling of plasma proteins associated with spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B | Fen Liu | Received |
SAT-168 | In vitro and in vivo characterization of the selective toll-like receptor 8 agonist GS-9688 | Stephane Daffis | Received |
THU-169 | Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology | Gian Paolo Caviglia | Received |
SAT-170 | Hepatic steatosis via controlled attenuation parameter measurements and diabetes contribute to persistent liver fibrosis in the era of long-term nucleoside analogue therapy for chronic hepatitis B | Wai-Kay Seto | Received |
FRI-170 | The NLRP3 inflammasome is activated in liver tissue of patients with newly diagnosed chronic hepatitis B virus infection | Georgios Germanidis | Received |
FRI-171 | Viral Dominance patterns in hepatitis delta patients are associated with distinct systemic inflammatory patterns which influence response to interferon therapy | Gunnar Lewon Lutterkort | Received |
FRI-172 | Prediction for the incidence of hepatocellular carcinoma in patients with chronic hepatitis B after administration of nucleos(t)side analog | Hideaki Takahashi | Received |
SAT-172 | Predictors for clinical relapse within 2 year off-ETV therapy in HBeAg negative chronic hepatitis B patients | Wen-Juei Jeng | Received |
THU-172 | Experiences from one of the largest treatment programs for chronic hepatitis B in sub-Saharan Africa | Hailemichael Desalegn | Received |
THU-173 | Nucleic acid polymer REP2139 monotherapy reveals a short half-life of serum HBsAg in HBeAg+ chronically infected hepatitis B virus patients | Andrew Vaillant | Received |
SAT-173 | Revisit HBsAg for HBeAg-negative chronic hepatitis B undergoing peginterferon treatment: a multicenter pooled-analysis study | Yin Chen Wang | Received |
FRI-173 | Relationship between HBsAg, HBV DNA, covalently closed circular DNA and fibrosis stage in chronic HBV (HBeAg-negative) patients | Konstantin Kozlov | Received |
SAT-174 | Reduced hepatitis B and D viral entry using novel clinically-applied inhibitors of the sodium taurocholate co-transporting polypeptide | Joanne Donkers | Received |
FRI-175 | High rate of progression to cirrhosis in patients with chronic hepatitis B (CHB) and non-alcoholic fatty liver (FL) | Jie Li | Received |
THU-175 | Baseline and early on-treatment HBsAg level to predict HBsAg loss in nucleotide analog suppressed and HBeAg cleared chronic hepatitis B patients by switching to peginterferon alfa-2a: exploratory results of NEW SWITCH study | Hong Ren | Received |
SAT-175 | Comparison of HDV mono-infection with genotype 1 and 3 in CRPISPR/Cas generated humanized NTCP mice and human liver chimeric mice | Katja Giersch | Received |
FRI-176 | Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study | Evan Brian Cunningham | Received |
SAT-176 | Serum HBV pgRNA can serve as clinical marker for cccDNA activity in patients with HBV mono and HBV/HDV co-infection | Lena Allweiss | Received |
THU-176 | A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population | James Hamilton | Received |
SAT-177 | An early step of Hepatitis B virus infection is dependent on the nuclear receptor for bile acids, farnesoid X receptor alpha | Patrice Andre | Received |
FRI-177 | Community pop-up clinic: a harm reduction strategy to engage hepatitis C virus infected injection drug users | Ghazaleh Kiani | Received |
FRI-178 | Evaluation of a sequence-based method for hepatitis C genotyping (Deepchek SingleRound PCR and NS5B/5´UTR sequencing) and comparison with VERSANT HCV Genotype 2.0 assay (InnoLiPA) | Greet Boland | Received |
SAT-179 | Hepatitis B Virus infection alters the transcriptional regulation of FXR-dependent microRNAs | Philipp Fritze | Received |
THU-179 | Enhancing detection and treatment of chronic hepatitis C related liver disease in vulnerable adults through a dedicated homeless hostel-based liver service: Vulnerable Adults LIver Disease Study | Ahmed Hashim | Received |
FRI-179 | Integrated healthcare system implementation of one time hepatitis C virus testing for patients born between 1945 and 1965 with linkage to care | James M Levin | Received |
THU-180 | Change in the trajectory of MELD scores in liver transplant candidates with hepatitis c in the direct acting antiviral era | Allison Kwong | Received |
FRI-180 | Late presentation of patients with chronic hepatitis C | Janne Fuglsang Hansen | Received |
SAT-180 | CRV431 and CMX157: Anti-HBV combination effects in vitro between a cyclophilin inhibitor and a nucleotide prodrug | Robert Thomas Foster | Received |
SAT-181 | The cyclophilin inhibitor CRV431 prevents both cyclophilin A-HBx complex formation and HBV replication | Robert Thomas Foster | Received |
FRI-181 | A behavioral Intervention improves the rate of hepatitis C treatment initiation among HIV/HCV coinfected patients: results of a randomized controlled trial | Jeffrey J Weiss | Received |
THU-181 | Interferon lambda 4 CC host genetic variant is linked with spontaneous hepatitis C virus clearance for genotypes 1, 2, and 3 | Anders Widell | Received |
SAT-182 | Hepatitis B virus X RNA is present in cell culture-derived virus preparations and plasma from chronically infected patients | Rudolf Beran | Received |
FRI-182 | Linkage to care of HBsAg and anti-HCV positive patients after a systematic screening approach in the German primary care setting | Johannes Wiegand | Received |
THU-182 | Declining prevalence and increasing awareness of hepatitis C virus infection in Italy: A population-based survey | Antonio Massimo Ippolito | Received |
SAT-183 | Hepatic expression of oncogenes Bmi1 and Dkk1 can be induced by treatment with Hepatitis B virus particles or Lipopolysaccharide in vitro and is up-regulated in liver biopsies of patients with chronic HBV infection | Ruth Broering | Received |
FRI-183 | Population level outcomes and cost-effectiveness of expanding guidance for age-based hepatitis C testing in the United States | Joshua A Barocas | Received |
THU-183 | Aerobic exercise and physical activity interventions in the management of hepatic manifestations of chronic hepatitis C; a systematic review | Ann Marie Monaghan | Received |
THU-184 | An assessment of physical activity levels and cardiorespiratory fitness in individuals living with hepatitis C | Ann Marie Monaghan | Received |
FRI-184 | CHESS - curing hepatitis C: effect on the endothelium and cardiovascular risk | Joshua S Davis | Received |
SAT-184 | Insulin enhances HBV replication and interferes with antiviral activity of IFN-a | Sandra Marie-Ange Phillips | Received |
SAT-185 | Early function modulation and reprogramming of Kupffer cells promote establishment and maintenance of HBV infection | Suzanne Faure-Dupuy | Received |
THU-185 | High-risk behaviour in a cohort of HIV/hepatitis C coinfected gay and bisexual men commencing hepatitis C treatment | Joseph S Doyle | Received |
THU-186 | Expression of NK cell receptors in childhood malignancy survivours in children with chronic hepatitis C | Anna Mania | Received |
SAT-186 | Peripheral and intrahepatic virological phenotyping in eAg negative chronic hepatitis B to evaluate risk of disease progression and hepatocellular carcinoma in the "grey-zone" viral load cohort | Valentina Svicher | Received |
FRI-186 | Treatment of chronic hepatitis C virus (HCV) infections with direct acting antivirals in the New Mexico state prison system using the project ECHO model | Karla Thornton | Received |
THU-187 | Low hepatitis C virus prevalence among human immunodeficiency virus+ individuals in Sub-Saharan Africa | Anne Loarec | Received |
SAT-187 | Hepatitis B virus production is enhanced through early autophagic flux but degraded through autophagosome-lysosome fusion | Yong Lin | Received |
FRI-188 | IL6-174GG genotype is associated with diabetes mellitus type 2 in patients with chronic hepatitis C | Luciana Diniz Diniz Silva | Received |
THU-188 | Hepatitis B testing in a large cohort of U.S. hepatitis C virus -infected patients | Anne C Moorman | Received |
SAT-188 | impact of long-term tenofovir disoproxil fumarate treatment on bone metabolism and skeletal muscle function in mouse | Yu-Xuan Luo | Received |
SAT-189 | The e antigen of the Hepatitis B virus enables evasion of Type 1 Interferon immune response | Zina Valaydon | Received |
FRI-189 | Muscle mass is a protector factor against low bone mineral density in hepatitis C | Luciana Diniz Silva | Received |
THU-189 | An audit of hepatitis C screening and referral patterns to a specialist hepatology service in a secondary care facility in the UK | Anthony Pratt | Received |
FRI-190 | Long-term fibrosis improvement after sustained virologic response in patients with chronic hepatitis C and advanced fibrosis or cirrhosis - pre-treatment cirrhosis, older age and high body mass index increases the risk for persisting fibrosis | Magnus Hedenstierna | Received |
SAT-190 | Determinants of the future burden of hepatocellular carcinoma after eradication of hepatitis C virus among cirrhotic patients | Prowpanga Udompap | Received |
THU-190 | Prevalence of hepatitis C in the spanish population. the prevhep study (ethon cohort) | Antonio Cuadrado Lavin | Received |
THU-191 | High incidence of persistently altered liver tests after sustained virological response with direct-acting antiviral in hepatitis C monoinfected and HIV-coinfected patients | Antonio Olveira | Received |
SAT-191 | The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients | Rachna Shridhar | Received |
FRI-191 | Survival in patients with chronic hepatitis C and mild-moderate fibrosis according to antiviral treatment response | Marc Puigvehí | Received |
FRI-192 | An approach to hepatitis C Virus epidemiology: analysis in 7602 patients of orthopaedic surgery | Maria Pipa-Muniz | Received |
SAT-192 | Prevalence of thyroid dysfunction among 21672 Egyptian patients with chronic HCV genotype IV | Zeinab Abdellatif | Received |
FRI-193 | A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit | Marianne Byrne | Received |
THU-193 | HCV-infected people who inject drugs (PWID): engagement in care and treatment, and prevention of reinfection | Arshia Alimohammadi | Received |
FRI-194 | DAA treatment scale-up in HIV/HCV co-infection: Characterisinga population at risk for reinfection | Marianne Martinello | Received |
THU-194 | Large-scale screening is not useful to identify individuals with hepatitis B or C virus infection: results of an interim analysis | Astrid Marot | Received |
SAT-194 | Low rates of hepatitis C virus (HCV) testing and HCV awareness among individuals at high risk for chronic HCV infection among an underserved safety-net population | Robert Wong | Received |
FRI-195 | Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals? | Marjolein Van Tilborg | Received |
THU-195 | Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: The SToP-C study | Behzad Hajarizadeh | Received |
SAT-195 | Impact of cryoglobulinemia on HCV viral load measurements of different molecular diagnostic systems | Gian Maria Prati | Received |
FRI-196 | Can dried blood spots be used for diagnosis of chronic hepatitis C virus infection, even if they are stored under non-ideal conditions? | Marjolein Van Tilborg | Received |
SAT-196 | Validation of the role of FIB-4 and APRI in the assessment of hepatic fibrosis and prediction of risky varices in Egyptian patients with chronic hepatitis C (genotype 4) | Saeed M. El-Nahaas | Received |
THU-196 | Injecting heroin - how long until hepatitis C infection obtained? | Brian Stephens | Received |
FRI-197 | Association between improved liver function and selenium depends on C718T polymorphism in 3´- untranslated region of glutathione peroxidase 4 and in humans | Nataliya Rohr-Udilova | Received |
SAT-197 | Abnormal microvasculature in chronic viral hepatitis | Samantha Sarcognato | Received |
FRI-198 | The impact of sustained virological response on long term risk of decompensated cirrhosis: the BC hepatitis testers cohort | Naveed Z. Janjua | Received |
THU-198 | Cross-sectional assessment of >20,000 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US | Jacqueline Reeves | Received |
THU-199 | The number of small low-density lipoprotein particles is decreased by hepatitis C virus G1b infection | Chika Kinoshita | Received |
FRI-199 | Abbott HCV core Ag and HCV RNA comparison study in country of Georgia | Nazibrola Chitadze | Received |
SAT-199 | Predictors of minimal hepatic encephalopathy in asymptomatic HCV patients before and after antiviral treatment: preliminary results from the EMERALD study | Sharon Levy | Received |
SAT-200 | Hepatocellular Carcinoma in Patients with Chronic Hepatitis C and Cirrhosis in Denmark | Sofie Hallager | Received |
FRI-200 | Trends in hepatitis C-related mortality in Switzerland | Francesco Negro | Received |
THU-200 | High prevalence of concomitant substance abuse and mental health disorders in an urban underserved FQHC-based hepatitis C virus treatment program | Christian Boyd Ramers | Received |
SAT-201 | Gender differences on long-term outcomes in patients with dual chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infection | Pauline Nguyen | Received |
THU-201 | Diversity of the association of serumlevelsand genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C | Chung-Feng Huang | Received |
SAT-202 | Impact of amino acid substitutions of HCV core region on hepatocarcinogenesis and hepatocellular oxidative stress in HCV infection | Takeshi Chida | Received |
FRI-202 | Gender differences in liver disease progression by ethnicity in patients with chronic hepatitis C virus (HCV) mono-infection | Pauline Nguyen | Received |
THU-202 | Characterisation of resistance associated substitutions in direct acting antivirals treatment naive patients with genotype 3 hepatitis C virus | David Anthony Smith | Received |
THU-203 | Prevalence and genotype distribution of hepatitis C virus in Georgia: a 2015 nationwide population-based survey | Davit Baliashvili | Received |
FRI-203 | Epidemiology and treatment of hepatitis C virus infection in China in 2013-2015: a hospital-based population study | Peng Hu | Received |
FRI-204 | TM6SF2, MBOAT7 and PNPLA3 genotypes in patients with untreated HCV chronic hepatitis and alcohol intake | Pietro Lampertico | Received |
SAT-204 | Resistance analysis in the MAGELLAN-1 Study (Part 2): Glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors | Tami Pilot-Matias | Received |
THU-204 | Understanding factors associated with hepatitis c spontaneous viral clearance: a meta-analysis | Dewi Nur Aisyah | Received |
FRI-205 | Pooled resistance analysis in HCV genotype 1-6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials | Preethi Krishnan | Received |
THU-205 | Search for anti-hepatitis C virus positive patients lost in the health system: analysis of the absence of referring and the abandonment of the patient | Elena Martinez Crespo | Received |
THU-206 | Rate and predictive factors of spontaneous hepatitis C virus clearance after acute infection in human immunodeficiency virus-positive subjects | Emanuela Messina | Received |
SAT-206 | Field evaluation of Xpert HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples | Tanya Lynn Applegate | Received |
FRI-206 | A novel single daily fixed dose combination of sofosbuvir 400 mg + ribavirin1000 mg + egcg 400 mg is superior to the standard of care as an anti-viral and safer causing less hemolysis in patients with chronic hepatitis C | Gamal Shiha | Received |
SAT-207 | Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools | Tanya Lynn Applegate | Received |
FRI-207 | Active versus passive follow-up examination of patients with chronic hepatitis C during Sofosbuvir/Ledipasvir treatment | Ganbolor Jargalsaikhan | Received |
FRI-208 | Rapid liver fibrosis regression after sustained virological response in HCV patients treated with direct acting antivirals | Gema Maria Lledó Ibáñez | Received |
SAT-208 | Correlation between prevalence of hepatitis B and C virus infection and mortality of hepatocellular carcinoma in Uvs province, Mongolia | Uurtsaikh Baatarsuren | Received |
THU-208 | Performance of the validated EGCRISC screening tool in chronic hepatitis C infection detection after application in the Egyptian setting | Engy Mohamed El-Ghitany | Received |
THU-209 | In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with daas is related to decline in liver inflammation | Adam Winters | Received |
SAT-209 | Drop of FGF19 levels in patients with HCC development following DAA therapy for chronic hepatitis C | Vanessa Stadlbauer | Received |
FRI-209 | Platelets represent an independent predictor of sustained virological response (SVR) in patients with advanced chronic hepatitis C (CHC) treated with current direct acting antiviral(s) (DAA). HERACLIS: Hellenic multicenter real-life cohort study | George Papatheodoridis | Received |
THU-210 | Factors that influence the improvement of serum albumin during interferon-free sofosbuvir/ledipasvir therapy for Japanese patients with chronic hepatitis C virus infection | Akira Kawano | Received |
SAT-210 | Regeneration linked miRNA in acute liver failure can predict clinical recompensation after DAA associated HCV cure: a novel biomarker to inform treatment ion in decompensated HCV cirrhosis? | Siamak Salehi | Received |
FRI-210 | An outbreak of acute hepatitis C GT1b in onco-hematological patients. Treatment with Sofosbuvir+Ledipasvir and concomitant chemotherapy | Giovanni Battista Gaeta | Received |
FRI-211 | Direct Acting Antivirals in patients with HCV-associated mixed cryoglobulinemia: real life safety and efficacy | Monica Schiavini | Received |
SAT-211 | Impact of genotype 3 on clinical outcome in patients with hepatitis C: both diabetes meliitus and liver disease progression | Wayel Zanjir | Received |
SAT-212 | Hepatitis C: Awareness Through to Treatment (HepCATT) study: Evaluation of an intervention designed to increase diagnosis and treatment of patients with hepatitis C virus infection in drug treatment settings | Matthew Hickman | Received |
FRI-212 | DAA-based treatment in HCV and HIV/HCV co-infected patients in real world: data from a large single-centre experience | Michele Milella | Received |
THU-212 | Markedly improvement of glycaemic control in diabetic patients with chronic hepatitis C achieving sustained virologic response after direct acting antiviral therapy: results of a prospective controlled study | Alessia Ciancio | Received |
SAT-213 | Successful Hepatitis C treatment with direct acting antivirals leads to a rapid on-treatment decrease of liver stiffness with a slower gradual decrease of spleen stiffness | Wim Verlinden | Received |
THU-213 | Impact of IL28B genotype on response rates in hepatitis C virus cirrhotic patients treated with new DAA regimens: experience of a single center | Paola Ponzo | Received |
THU-214 | Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone | Alison Boyle | Received |
SAT-214 | Epidemiology of hepatitis C infections in patient population in Northeastern China: a cross-sectional study | Yue Hu | Received |
FRI-214 | Real world outcomes of DAA therapy for chronic hepatitis C virus infection in the HCV Research UK National cohort | Michelle Cheung | Received |
SAT-215 | Elevated serum wisteria floribunda agglutinin-positive mac-2-binding protein levels associated with risks of diabetes and end-stage renal diseases among patients with hepatitis C virus infection | Yu-Ju Lin | Received |
THU-215 | Risk of cardiovascular and cerebrovascular events in hepatitis C patients following completion of direct-acting antiviral therapy: a retrospective cohort study | Anand P. Chokkalingam | Received |
THU-216 | Persistence of hepatitis c virus core antigenemia after sustained virological response is associated with worsening of liver function and increased risk of hepatocellular carcinoma | Amr Shaaban Hanafy | Received |
SAT-216 | The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States | Yuri Sanchez Gonzalez | Received |
FRI-216 | Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life | Guia Cerretelli | Received |
FRI-217 | Modeling vaccine and DAA treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago | Harel Dahari | Received |
SAT-217 | Extra-hepatic manifestations from hepatitis C virus infection related to female infertility and adverse pregnancy outcomes: A real-world observation | Yuri Sanchez Gonzalez | Received |
THU-217 | SVR reduces ethnic disparities in progression to advanced liver disease in patients with chronic hepatitis C | An K. Le | Received |
THU-218 | Risk of hepatitis B virus reactivation during exposure to hepatitis C virus treatment: an analysis of US ambulatory electronic medical record data | Anand P. Chokkalingam | Received |
SAT-218 | Health-related quality of life in children with hepatitis C viral (HCV) infection treated with Sofosbuvir and Ribavirin | Zobair M Younossi | Received |
FRI-218 | Sofosbuvir-based therapy in patients with chronic hepatitis C virus infection and malignancies – a prospective observational study of 136 patients | Harrys Antonio Torres | Received |
SAT-219 | Significant incidence of psyquiatric disorders despite rapid and positive impact of direct acting antivirals on quality of life | Zoe Mariño | Received |
THU-219 | Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir plus/minus ribavirin for treatment of hepatitis C virus genotype 1b compensated cirrhosis in patients aged 70 years or older | Anca Trifan | Received |
FRI-219 | Full dose, daily sofosbuvir treatment in end-stage renal disease: tolerability & safety of largest ESRD patient cohort exposed to this drug | Hector Enrique Nazario | Received |
FRI-220 | Excellent cure rates in largest ESRD patient cohort who completed treatment with full dose, daily sofosbuvir-based regimens | Hector Enrique Nazario | Received |
THU-220 | Early regression of liver fibrosis evaluated by non-invasive methods after successful antiviral therapy in patients with HCV genotype 1b compensated cirrhosis | Anca Trifan | Received |
SAT-220 | Pre-emptive post-liver transplant hepatitis C virus treatment with daas: proof of concept from a pilot study | Luisa Pasulo | Received |
SAT-221 | High sustained viral response among hepatitis C virus genotype 3 patients with advanced liver fibrosis - real-world data of HCV elimination program in Georgia | Maia Butsashvili | Received |
FRI-221 | The „HCV Advisor" App - A web-based mobile application to identify suitable treatments with direct antiviral agents for chronic hepatitis C infection | Heiko Fruehauf | Received |
FRI-222 | Impact of directly acting antiviral drugs during treatment of decompensated cirrhosis with chronic hepatitis C | Vivek Anand Saraswat | Received |
THU-222 | The effect of ribavirin dosage on the kinetics of viral load decline and drug exposures in plasma and liver with OBV/PTV/r + DSV treatment in patients with chronic hepatitis C virus genotype 1a infection | Andrew H Talal | Received |
FRI-223 | New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society | Hugo Cheinquer H | Received |
SAT-223 | Impact of sustained virological response with DAAs in patients with compensated HCV cirrhosis and endoscopic esophageal varices study | Marc Puigvehí | Received |
SAT-224 | Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience | Marco Sanduzzi Zamparelli | Received |
THU-224 | Liver stiffness evaluated by means of ARFI is related not only to fibrosis in patients with hepatitis C virus-related chronic hepatitis | Annamaria Gesualdo | Received |
FRI-224 | Ribavirin free versus Ribavirin containing therapy with all second generation direct acting antivirals for the treatment of hepatitis C virus genotype 1 infection; a pooled analysis of 4501 patients | Hussien Ahmed | Received |
THU-225 | Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon gives very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C: final results of the 4WIDUC study | Anne Lindebo Holm Oevrehus | Received |
FRI-225 | Sustained Viral Response in patients who fail to complete hepatitis C treatment with Direct Acting Antivirals | Iain Hay | Received |
FRI-226 | Response guided addition of Sofosbuvir to pegylated interferon and ribavirin cures greater than 90% of patients with Genotype 3 infection and F0-2 disease | Iain Hay | Received |
THU-226 | Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy | Francesca Ceccherini-Silberstein | Received |
SAT-226 | Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study | Maria-Carlota Londoño | Received |
THU-227 | Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study | Antonio Massimo Ippolito | Received |
THU-228 | High sustained virological response rates in hepatitis C genotypes 1a and 4 patients treated with elbasvir and grazoprevir and basal viremia >800.000 UI/mL | Antonio Olveira | Received |
FRI-228 | Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirhhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry | Irene Cacciola | Received |
SAT-228 | Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: The CHAMPS Study | Mark Sulkowski | Received |
FRI-229 | No adverse renal side effects in patients with mild to moderate renal dysfunction treated with Sofosbuvir | Iris Kuo | Received |
FRI-230 | The presence of two or more baseline NS5A resistance associated substitutions jeopardizes DAA treatment success in HCV patients | Itziar Carrasco Garcia | Received |
SAT-230 | Phase 1 study assessing the safety, pharmacokinetics, and antiviral activity of CC-31244, a pan-genotypic, potent non-nucleoside NS5B polymerase inhibitor for the treatment of hepatitis C virus infection | Mark Sulkowski | Received |
THU-230 | The effect of directly acting antivirals treatment on inflammatory status in HCV-infected patients, including those with recurrence of HCV-infection after liver transplantation: preliminary results of a prospective monocentric pilot study | Barbara Lattanzi | Received |
SAT-231 | Treatment of patients with hepatitis C virus genotype 5 and 6: descriptive analysis of the Hepa-C registry | Marta Hernández Conde | Received |
SAT-232 | Hepatitis C treatment with direct antiviral agents induce mild renal impairment | Marta Tejedor Bravo | Received |
THU-232 | The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments | Behzad Hajarizadeh | Received |
FRI-232 | Hepatitis C therapy delivered within and by a community addiction service: real life data shows SVR rates 90 | Jacquelyn McGinley | Received |
THU-233 | Reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection in a community based setting | Beshoy Yanny | Received |
SAT-233 | High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: Integrated efficacy and safety analysis of genotype 1-6 patients without cirrhosis | Ed Gane | Received |
SAT-234 | Use of ledipasvir/sofosbuvir in patients with advanced chronic kidney disease (eGFR =30ml/min): a case series | Joseph Llewellyn | Received |
THU-234 | Grazoprevir-elbasvir based therapy is safe and effective in patients with chronic kidney disease GFR <30 and patients with end stage renal disease who are on renal replacement therapy in a community based setting | Beshoy Yanny | Received |
FRI-234 | Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study | Jason Grebely | Received |
FRI-235 | SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy | Jason Grebely | Received |
THU-235 | Direct acting antivirals improve neutrophil phagocytic capacity in chronic hepatitis C | Bettina Leber | Received |
SAT-235 | Plasma miR-122 levels in chronic hepatitis C patients achieving sustained virological response following DAA treatment with and without previous anti-miR-122 (RG-101) dosing | Meike H. van der Ree | Received |
SAT-236 | The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis | Michael Manns | Received |
THU-236 | Using all-oral hepatitis C virus therapy to reduce recurrent viremia and increase SVR | Arshia Alimohammadi | Received |
FRI-237 | HepCom: Impact of co-morbidities on the final success of direct antiviral agents therapy in hepatitis C | Javier Ampuero | Received |
SAT-238 | Drug-drug interactions of high prevalence in a real world hepatitis C treatment setting: the impact on treatment and the implications for patient management | Miriam Coghlan | Received |
THU-238 | Feasibility and acceptability of a group medical visit intervention to improve hepatitis C virus treatment uptake among persons who inject drugs (PWID) in a primary care setting | Brianna Norton | Received |
FRI-238 | Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection: an integrated analysis | Jean-Francois Dufour | Received |
THU-239 | Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: Retrospective data analyses from the TRIO Network | Bruce Bacon | Received |
FRI-239 | Analysis of the real-world treatment effectiveness of elbasvir/grazoprevir | Jeffrey Scott Mc Combs | Received |
FRI-240 | Obesity and high body weights predict ledipasvir/sofosbuvir treatment failure | David J. Witt | Received |
THU-240 | Outcome of patients with compensated liver cirrhosis with hepatitis B virus+hepatitis C virus coinfection treated with paritaprevir/ ombitasvir /ritonavir, dasabuvir with ribavirin: a national cohort study | Carmen Preda | Received |
THU-241 | Second generation direct acting antiviral agents improve clinical resource utilization required for hepatitis C eradication | Charles Mahoney | Received |
FRI-241 | Hepatitis C Care Continuum: Experience of an Emergency department screening programme | Jennifer Lee | Received |
SAT-241 | Outcomes of daclatasvir + sofosbuvir + riba in HEP C G3 patients who relapsed with SOF + RIBA combination therapy | Muzaffar Lateef Gill | Received |
SAT-242 | Comparison of vibration-controlled transient elastography (VCTE) with aspartate aminotransferase-to-platelet ratio Index (APRI) and platelet count for Identification of esophageal varices in patients with cirrhosis | Muzaffar Lateef Gill | Received |
FRI-242 | Changes in markers of liver function in hepatitis C virus genotype 1b Asian patients with compensated cirrhosis treated with ombitasvir/paritaprevir/ritonavir plus dasabuvir with ribavirin in the ONYX-II study | Jeong Heo | Received |
THU-242 | Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis | Cheng Wang | Received |
THU-243 | Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of hepatitis C virus -infected patients treated with recommended regimens | Chiara Masetti | Received |
FRI-243 | Cure of chronic hepatitis C patients receiving direct-acting antivirals correlated with partial restoration of HCV-specific T cell responses | Jijing Shi | Received |
SAT-243 | Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C | Naoki Kawagishi | Received |
FRI-244 | Fibrosis regression in chronic hepatitis C patients after treatment with direct-acting antiviral agents is more effective than before – comparison of different noninvasive methods | Joana Rita Oliveira Alves Rita Carvalho | Received |
THU-244 | Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of hepatitis C virus infected patients with chronic kidney disease | Chiara Masetti | Received |
SAT-244 | Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network | Naoky Tsai | Received |
SAT-245 | Direct-acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: real-life data | Nathalie Scherz | Received |
FRI-245 | Total cholesterol and low-density lipoprotein increases after treatment with direct-acting antiviral agents – Implications in the future? | Joana Rita Oliveira Alves Santos Carvalho | Received |
FRI-246 | Successful implementation of HCV treatment in two large HIV clinics in Amsterdam: HCV treatment cascade of care | Job Saris | Received |
SAT-246 | Are DAAs reducing barriers for HIV co-infected and people who inject drugs? A population based cohort study | Naveed Janjua | Received |
FRI-247 | Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R) | Johannes Vermehren | Received |
SAT-247 | Assessment of glomerular filtration rate in hepatitis C virus patients after reaching sustained virologic response | Nelson Roberto Reyes Campos | Received |
SAT-248 | DAA-based regimens in HBsAg/anti-HCV positive patients: the need to control HBV replication to avoid HBV reactivation | Nicola Coppola | Received |
FRI-248 | Clinical and virological characteristics of patients with chronic hepatitis C virus (HVC) infection and failure to multiple direct acting antiviral (DAA) therapies | Johannes Vermehren | Received |
THU-249 | Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus genotype 3 infection | Christophe Hezode | Received |
SAT-249 | Real world experience of direct acting antiviral agents in hepatitis C virus genotype 4: encouraging outcomes from a UK-based cohort | Nina Stafford | Received |
FRI-249 | Efficacy and safety of Simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy | John Dillon | Received |
FRI-250 | Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir +/- ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis – final results of the REV1TAL study | John Samuel Lubel | Received |
THU-250 | Treatment of "acute" hepatitis C virus in human immunodeficiency virus-infected men with short-course sofosbuvir/ledipasvir | Daniel Seth Fierer | Received |
FRI-252 | Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in Germany | Jörg Petersen | Received |
SAT-252 | Changes in the lipid profile in hepatitis C virus infected patients treated with direct-acting antivirals | Pedro Linares | Received |
THU-253 | Effects of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection on serotonin metabolism, depression scores and fatigue | Daphne Hahn | Received |
FRI-253 | Adherence to SmPC recommendations in real-world practice in the treatment of monoinfected patients with chronic genotype 1 or 4 HCV infection with direct-acting antivirals | José Luis Calleja Panero | Received |
FRI-254 | Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice | José Luis Calleja Panero | Received |
THU-254 | Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin | Darshan Mehta | Received |
THU-255 | Treatment outcomes of hepatitis C virus recombinant form 2k/1b with sofosbuvir based regimens in Georgia | David Metreveli | Received |
FRI-255 | INTER-COLLaborative HEPatitis C: real-world treatment of hepatitis C patients by non-expert specialist providers in small and medium size Portuguese hospitals | Jose Ramos | Received |
SAT-255 | Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world | Philippe Halfon | Received |
SAT-256 | Molecular characterization of Hepatitis C virus resistance-associated substitutions after interferon-free treatment failure by massive parallel sequencing | Qian Chen | Received |
FRI-256 | Suitability of HCV treatment in primary care settings for individuals with HIV/hepatitis C coinfection | Joseph S Doyle | Received |
THU-256 | Hepatitis C: year 1 real life results from the All Wales hepatitis C roll out programme | David Samuel | Received |
FRI-257 | Short-term effect of DAA IFN-free regimens on liver stiffness | Juan A. Pineda | Received |
SAT-257 | Improved virological outcomes and excellent safety profile in genotype 3 HCV-infected cirrhotic patients after an extended 24-weeks course of daclatasvir, sofosbuvir + ribavirin: insights from a real-life multicenter study | Raffaella Lionetti | Received |
SAT-258 | Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in hepatitis C virus genotype 1- infected patients with compensated cirrhosis and multiple comorbidities | Raluca Cezara Popa | Received |
THU-258 | 12 weeks of sofosbuvir, daclatasvir and ribavirin for GT3 patients with cirrhosis | Debbie Troland | Received |
FRI-258 | Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome | Julia Dietz | Received |
SAT-259 | An exploratory study to evaluate immune restoration after removal of viral antigen in adults with genotype 1a chronic hepatitis C virus infection treated with ombitasvir/oparitaprevir/ritonavir + dasabuvir and ribavirin for 12 weeks | Jacinta A. Holmes | Received |
FRI-259 | High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis | Julia Schwarz | Received |
THU-259 | Retreatment of hepatitis C virus daa failures in real life: Easy and difficult to cure patients | Denis Ouzan | Received |
FRI-260 | Efficacy of therapy against chronic hepatitis C virus genotype 1 infection in HIV-coinfected patients with several interferon-free DAA combinations: Real life data from the HEPAVIR-DAA Cohort | Juan A Pineda | Received |
SAT-260 | Lipid modification in hepatitis C virus-monoinfected patients treated with direct acting antivirals | Regina Juanbeltz | Received |
THU-260 | Hepatitis C virus-RNA decay with direct acting antivirals in human immunodeficiency virus/hepatitis C virus coinfected patients | Diletta Barbanotti | Received |
THU-261 | Effect of interferon free antiviral therapy on glomerular and tubular kidney involvement in hepatitis C virus child-A cirrhosis | Donatella Palazzo | Received |
SAT-261 | Real world experience: Treating Hepatitis C in Alice Springs, Australia 2007-16 | Robert Gordon Batey | Received |
THU-262 | Prospective study of autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct acting antivirals | Doroteo Acero Fernández | Received |
FRI-262 | CERTAIN-1: efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis | Fumitaka Suzuk | Received |
SAT-262 | Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN | Roberta D´ambrosio | Received |
SAT-263 | Optimization of direct antiviral agent treatment schedule in hepatitis C virus genotype 3 infection: an Italian, multicentetric experience in real-life setting | Filomena Morisco | Received |
FRI-263 | Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection with and without cirrhosis | Tsunamasa Watanabe | Received |
THU-263 | Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis | Edward Gane | Received |
SAT-264 | Sustained virological response in HCV patients treated with daclatasvirsofosbuvir, with or without ribavirin: a multicenter, field-practice experience | Rodolfo Sacco | Received |
SAT-265 | DAAs increase serum VEGF level: a rationale for tumour risk recurrence during anti-HCV treatment | Rosanna Villani | Received |
FRI-265 | Benefit of direct-acting antiviral therapy in hepatitis C virus (HCV) monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia | Kerstin Hartig-Lavie | Received |
SAT-266 | Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy | Sabela Lens | Received |
THU-267 | Effectiveness and safety of sofosbuvir-based regimens for Japanese patients with hepatitis C virus genotype 1b or 2 infection: real life experience from a multicenter cohort | Eiichi Ogawa | Received |
THU-268 | High efficacy of 8 weeks of ledipasvir/sofosbuvir in real-world treatment | Eleanor Wilson | Received |
SAT-268 | Effect of hepatitis C treatment with ombitasvir/paritaprevir/ritonavir+dasabuvir regimen on patient`s health related quality of life: Analysis of Phase 3a and phase 3b clinical trials | Darshan Mehta | Received |
THU-269 | Changes in renal function in patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents | Eleni Theocharidou | Received |
SAT-269 | Drop-out rate due to HCC progression is not affected by HCV eradication with DAAs in patients awaiting liver transplantation | Sarah Shalaby | Received |
FRI-270 | Antiviral therapy in patients with chronic hepatitis C related hepatocellular carcinoma responding to palliative treatment | Kwan Sik Lee | Received |
THU-270 | Management of drug-interactions with DAAs in Dutch human immunodeficiency virus/hepatitis C virus co-infected patients: adequate but not perfect | Elise Joëlle Smolders | Received |
SAT-270 | Results of hepatitis C treatment program among people who inject drugs | Sergii Filippovych | Received |
FRI-271 | Comparison of efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin between Asian and western HCV GT1b-infected patients | Lai Wei | Received |
THU-271 | Improvement of glycemic state among responders to sofosbuvir – based DAAs | Shereen Abdel Alem | Received |
SAT-271 | On-treatment HCV RNA monitoring is not a cost-effective means of identifying non-adherence and has no predictive value | Shirin Demma | Received |
FRI-272 | Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in Asian patients with genotype 1b chronic hepatitis C virus infection and compensated cirrhosis: ONYX-II post-treatment week 24 results | Lai Wei | Received |
SAT-272 | Characterization of novel GT-1b resistant-associated substitutions (RASs) selected by NS5A inhibitor-based regimens | Slim Fourati | Received |
THU-272 | Prevalence of serum non organ specific antibodies in patients with chronic hepatitis c and their influence in direct-acting antivirals therapy | Endrit Shahini | Received |
SAT-273 | Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1 6 and chronic kidney disease: an integrated analysis | Stan Pol | Received |
FRI-273 | Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results | Wan-Long Chuang | Received |
FRI-274 | Efficacy and safety of Direct-Acting Antiviral Drugs in patients with thalassemia major and crhonic hepatitis C: a preliminary report of a single italian center | Laura Ponti | Received |
THU-274 | Lack of clinical benefit of direct acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis | Estefania Berge | Received |
THU-275 | High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry | Ester Badia Aranda | Received |
FRI-275 | No increased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct acting anti-viral treatment for hepatitis C virus: a cohort study using large-scale administrative medical claims data | Anand P. Chokkalingam | Received |
FRI-276 | In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir | Leen Vijgen | Received |
THU-276 | Evolution of platelets in chronic hepatitis C infected patients and advanced liver fibrosis after direct-acting antiviral treatment | Ester Badia Aranda | Received |
SAT-276 | Effect of eradicating hepatitis c on alanine aminotransferase levels | Stefan Mauss | Received |
SAT-277 | Worsening of serum lipid profile after direct acting antiviral treatment | Stefano Gitto | Received |
FRI-277 | Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis | Letizia Marinaro | Received |
FRI-278 | Decrease of Interleukin-6 and Interleukin-8 blood levels after successful interferon-free anti-HCV treatment | Lorenzo Badia | Received |
SAT-278 | Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy | Stephan Moser | Received |
THU-278 | The eradicate-C study-curing people who are actively injecting drugs of hepatitis C: the first step to elimination | Farsana Ahmad | Received |
SAT-279 | Real-world treatment utilization and results in the renaissance of HCV Care: Analyses of treatment for 7,550 Patients from the TRIO Network | Steven Flamm | Received |
FRI-279 | Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort | Loreta A Kondili | Received |
THU-279 | Comorbidities and metabolic disorders associated to hepatitis C virus infection: their implications in the severity of the disease and overall mortality risk | Fátima Serejo | Received |
FRI-280 | Clinical characterization and economic impact evaluation of anti- HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) | Loreta A. Kondili | Received |
THU-280 | Real life retreatment of patients failing DAAs in Spain: data from the HCVREsp cohort | Federico García | Received |
FRI-281 | Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer | Luisa Cavalletto | Received |
THU-281 | Low rate of drug-drug interaction management during interferon-free simeprevir therapy - An integrated analysis of interventional and observational clinical studies | Fiona Marra | Received |
FRI-282 | Genotype 3 infection in DAA era: reports of a real life NORTHERN ITALY NETWORK FOR VIRAL HEPATITIS after 2 years by the start | Luisa Pasulo | Received |
SAT-282 | The macrophage activation marker, soluble CD163 is associated with hepatic inflammation and fibrosis in chronic viral hepatitis C and declines during effective direct-acting antiviral therapy | Tea Lund Laursen | Received |
THU-282 | Successful management of drug interactions with ritonavir-containing hepatitis C virus regimens in routine clinical practice | Fiona Marra | Received |
THU-283 | Changes in liver stiffness assessment in chronic hepatitis c patients treated with direct-acting antivirals: monocentric experience between 2015 and 2016 | Elke Maria Erne | Received |
SAT-283 | Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia | Tengiz Tsertsvadze | Received |
FRI-283 | The old patient in DAA era: real life reports on 5925 patients from the Lombardy HCV Network | Luisa Pasulo | Received |
FRI-284 | Virus-specific coexpression of T-bet and Eomes defines highly functional CD8 and CD4 T cells in hepatitis B virus infection | Hadi Karimzadeh | Received |
SAT-284 | Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia | Tengiz Tsertsvadze | Received |
THU-284 | Cost-effectiveness of elbasvir-grazoprevir association for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France | Franck Maunoury | Received |
FRI-285 | Hepatitis E virus-specific T cell responses against non-structural viral proteins in patients with ongoing and resolved hepatitis E | Jana Al-Ayoubi | Received |
THU-285 | Efficacy and safety of the fixed-dose combination regimen of MK3 MK-3682/grazoprevir/ruzasvir with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2) | Frank Dutko | Received |
FRI-286 | The impact of ERAP1 polymorphisms on virus-specific CD8+ T cell responses in an HLA*B27+ patient with acute hepatitis C virus infection | Janine Kemming* | Received |
SAT-286 | Outcome of liver transplantation in HCV infected patients – implications for antiviral treatment decisions | Thomas Kuntzen | Received |
THU-286 | Chronic hepatitis C in children in the Russian Federation: a multicenter study | Tamara Skvortsova | Received |
SAT-287 | Virological and clinical significance of detectable HCV-RNA below limit of quantification at End-of-Treatment in patients treated with direct antiviral agents | Ubaldo Visco Comandini | Received |
SAT-288 | The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution | Valeria Cento | Received |
THU-288 | Neutralizing activity of non-polyreactive monoclonal antibodies directed against the hepatitis C virus E2 glycoprotein isolated from patients with spontaneous resolution | Anne Olbrich | Received |
THU-289 | Infectious hepatitis C virus particle assembly is inhibited by paritaprevir and ombitasvir | David R Mcgivern | Received |
SAT-289 | Interferon-free direct-acting antiviral therapy decreases the rate of hepatocellular carcinoma recurrence in patients with chronic hepatitis C and advanced fibrosis | Victor Virlogeux | Received |
FRI-290 | Pegylated interferon alpha treatment rapidly clears hepatitis E virus infections in humanized mice | Thomas Vanwolleghem | Received |
THU-290 | Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals | Elena Perpiñán Mas | Received |
SAT-290 | Liver decompensation predicts ribavirin overexposure in HCV cirrhotic patients treated with direct-acting antiviral agents | Viola Guardigni | Received |
FRI-291 | KLRG1 impairs antiviral immunity of NK-cell in Individuals with Chronic Hepatitis B Virus Infection via the Akt pathway | Ming-Hong Li | Received |
SAT-291 | Impact of hepatoprotective medications on the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in hepatitis C virus genotype 1b-infected Asian patients with and without cirrhosis in the ONYX-I and -II studies | Wan-Long Chuang | Received |
SAT-292 | Liver function as measured by albumin-bilirubin score within decompensated patients receiving direct acting antiviral therapy within the Expanded Access Programme | Philip Johnson | Received |
FRI-292 | B-Cell depletion therapy with rituximab in patients with hepatitis C virus mixed cryoglobulinemic vasculitis improves B- and T-Cell phenotype and function | Poonam Mathur | Received |
THU-292 | Molecular mechanisms of fitness compensation in drug resistance-associated NS3 protease variants in hepatitis C | Georg Dultz | Received |
FRI-293 | Mucosal-associated invariant T lymphocytes are declined, activated, and exhausted in peripheral in chronic HBV-infected patients | Qian Liu | Received |
SAT-293 | Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C after living donor liver transplantation: a Japanese multicenter experience | Yoshihide Ueda | Received |
FRI-294 | Metabolic properties of epigenetically regulated adaptive versus conventional NK cells are conserved in chronic viral hepatitis | Anita Schuch | Received |
SAT-294 | Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: A UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naïve patients | Yuri Sanchez Gonzalez | Received |
THU-294 | Allelic variantes of Aurora B kinase gene can be related with fibrosis progression in chronic hepatitis C | Irene Francisco-Recuero | Received |
SAT-295 | A budget optimization analysis for the treatment and potential elimination of hepatitis C virus infection in the United States | Yuri Sanchez Gonzalez | Received |
FRI-295 | CCR5 T cells are primary responders to HCV subject to exhaustion and contribute to ongoing hepatic inflammation | Shikha Shrivastava | Received |
FRI-296 | Myeloid-derived suppressor cells: key players mediating immunosuppression via induction of regulatory T-cell by TGF-ß and IL-10 driven pathways in chronic HBV infection | Sourina Pal | Received |
SAT-296 | Direct acting antivirals did not increase early recurrences after curative treatment of HCV related hepatocellular carcinoma in comparison with IFN-based treatment | Yutaka Yasui | Received |
THU-296 | Hepatocyte single cell sequencing to identify transcript modulation by hepatitis C virus | Jose Daniel Debes | Received |
THU-297 | Multiple ascending dose study of seraprevir potassium, a nonstructural protein 3/4A replication complex inhibitor, in patients infected with hepatitis C virus | junqi niu | Received |
SAT-297 | Elbasvir/Grazoprevir effectiveness in patients with chronic hepatitis C and chronic kidney disease: real-world experience from the TRIO Network | Zobair Younossi | Received |
FRI-297 | Transcriptome profiles of NK and T cells associated with immune control in chronic hepatitis B patients treated with pegylated interferon alpha-nucleos(t)ide analogue sequential therapy | Upkar S. Gill | Received |
FRI-298 | Human leukocyte antigen and IL28B polymorphisms independently associated with hepatitis C virus RNA spontaneous clearance: a study from REVEAL-HCV cohort | Yu-Han Huang | Received |
THU-298 | Inosine triphosphate pyrophosphatase enhances the effect of ribavirin on hepatitis C virus cell culture infection | Kristina Nyström | Received |
SAT-298 | HEV as a cause of acute hepatitis acquired in Switzerland | Montserrat Fraga Christinet | Received |
THU-299 | Identification of glycogen synthase kinase 3 beta as a novel host factor of hepatitis C virus replication | Maged Saleh | Received |
SAT-299 | Solithromycin treatment for 13 weeks improves histological parameters in nonalcoholic steatohepatitis: results of an ongoing pilot study | Pierre Gholam | Received |
SAT-300 | The severity of steatosis does not influence liver stiffness measurements in patients with non-alcoholic fatty liver disease | Roberta Forlano | Received |
THU-300 | Viral load at 15 days after liver transplantation as a good predictor of fast liver fibrosis progression | Meritxell Llorens | Received |
FRI-300 | Disease spectrum of alcoholic liver disease in beijing 302 hospital from 2002-2013: a large tertiary referral hospital experience from 7422 patients | Ang Huang | Received |
SAT-301 | Prevalence of combined PNPLA3 and GCKR variant genotype is increased in patients with risk factors for alcoholic or non-alcoholic liver disease who have clinically significant serum pro-collagen III levels | Prarthana Thiagarajan | Received |
THU-301 | In vitro inhibition of hepatitis C virus with ribavirin is strain dependent and leads to RNA mutagenesis | Niels Mejer | Received |
FRI-301 | MAIT cell dysfunctions correlate with markers of intestinal integrity in ALD patients | Antonio Riva | Received |
FRI-302 | Variation in the use of corticosteroids for the treatment of acute severe alcoholic hepatitis in the post-STOPAH era: results of a UK national survey | Ashwin Dhanda | Received |
SAT-302 | Prevalence of nonalcoholic fatty liver disease in lean adolescents in the United States: an analysis of national health and nutrition examination survey data | Naim Alkhouri | Received |
THU-302 | MIV-802, a uridine nucleotide prodrug, is a more potent inhibitor of hepatitis C virus genotype 3 replication than sofosbuvir | Richard Bethell | Received |
THU-303 | Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance | Sofia R Bartlett | Received |
SAT-303 | Prevalence and risk factors of nonalcoholic fatty liver disease in metabolically healthy obese adolescents in the United States: an analysis of national health and nutrition examination survey data | Naim Alkhouri | Received |
FRI-303 | Intermediate (CD14++CD16+) monocytes from patients with acute severe alcoholic hepatitis are activated and functionally similar to classical (CD14++CD16-) monocytes | Ashwin Dhanda | Received |
FRI-304 | No consensus among nutritional assessment tools for identification of malnutrition in patients with alcoholic liver disease | Chetan Ramesh Kalal | Received |
SAT-304 | Can modest alcohol intake be dismissed as a co-factor in diabetic patients with non-alcoholic fatty liver disease? | Preya Janubhai Patel | Received |
FRI-305 | Ethanol-induced depletion of Akkermansia muciniphila drives alcoholic liver disease | Christoph Grander | Received |
THU-305 | Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes | Teresa Ng | Received |
SAT-305 | Relationship between fatty liver, coronary calcium score, multiple-sites atherosclerosis and 10-years Framingham Score | Raluca Pais | Received |
THU-306 | Transcriptional response to hepatitis C virus infection in the human liver | Tuyana Boldanova | Received |
SAT-306 | Ethnicity and outcomes in non alcoholic fatty liver disease: prospective evaluation of 1500 cases | Richard Parker | Received |
SAT-307 | Development and validation of an automated system for assessment of liver steatosis and fibrosis in routine histological images in patients with non-alcoholic fatty liver disease | Roberta Forlano | Received |
FRI-307 | Effect of alcohol on the IL-6 mediated inflammatory response in a new mouse model of acute-on-chronic liver injury | Ersin Karatayli | Received |
THU-307 | Exosomal miRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection | Zhongtian Qi | Received |
THU-308 | Direct antiviral agents therapy can induce a partial restoration of the antiviral immune functions in patients with chronic hepatitis C virus infection | Amalia Penna | Received |
FRI-308 | A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption | Flaminia Ferri | Received |
FRI-309 | Differential gender-related impact of PNPLA3 and CD14 polymorphism on the risk of developing alcoholic cirrhosis | Flaminia Ferri | Received |
THU-309 | Role of SerpinB3 in the stimulation of macrophage activation marker sCD163 in hepatitis C virus infected patients | Andrea Martini | Received |
SAT-309 | Obesity and steatosis severity affect diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease | Yong Jin Jung | Received |
THU-310 | Preferential recognition of hepatitis B virus-DNA integrated target by hepatitis B virus-specific CD8 T cells | Atefeh Khakpoor | Received |
FRI-310 | Hair ethyl glucuronide is a highly accurate and objective biomarker of continued alcohol use in patients with alcoholic cirrhosis | Frederik Nevens | Received |
SAT-310 | Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease | Salvatore Petta | Received |
SAT-311 | Emerging Increase in the prevalence and severity of nonalcoholic fatty liver disease: epidemiological study from general Mediterranean population | Salvatore Petta | Received |
THU-311 | Impaired T follicular helper cell-B cell axis in chronic HBV infection despite long-term antiviral treatment | Bhawna Poonia | Received |
FRI-311 | The effect of nurse performed telemedical video consultations for patients suffering from alcohol-related liver cirrhosis | Ghita Bellis Thygesen | Received |
THU-312 | MAIT cell frequency and function in blood and liver of hepatitis C virus mono- and hepatitis C virus/human immunodeficiency virus co-infected patients with mild versus advanced fibrosis | Boris Beudeker | Received |
SAT-312 | A randomized, double-blind, placebo-controlled study to evaluate the efficacy of a multispecies probiotic mixture in obese non-alcoholic fatty liver disease | Sang Bong Ahn | Received |
FRI-312 | Carcinogenic Etheno DNA-adducts in alcohol liver disease: correlation with cytochrome P-4502E1 and fibrosis | Helmut Karl Seitz | Received |
SAT-313 | Dynamic FDG-PET study of liver inflammation in non-alcoholic fatty liver disease | Souvik Sarkar | Received |
THU-313 | Identification of a highly cross-reactive CD8+ T cell repertoire that recognizes a hepatitis E virus peptide and an apoptotic epitope | Chai Fen Soon | Received |
FRI-313 | Iron promotes ADAM-17 mediated sCD163: TNF-a liberation and modulates inflammation in severe alcoholic hepatitis | Jaswinder Singh Maras | Received |
THU-314 | Macrophage-derived extracellular vesicles mediate a long-lasting innate immune response against hepatitis C virus | Chengcong Cai | Received |
FRI-314 | Physiologic Staging in alcoholic Liver Disease Predicts Death and Monitors Recovery | John Carl Hoefs | Received |
SAT-315 | Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies | Stuart Mcpherson | Received |
THU-315 | Hepatitis B virus affects dendritic cell activation and their crosstalk with natural killer cells | Claudia De Pasquale | Received |
FRI-315 | Effects of probiotics (Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) in the treatment of mild alcoholic hepatitis: randomized controlled multicenter study | Ki Tae Suk | Received |
SAT-316 | Paired biopsy analysis of human liver transcriptome before and 1 year after bariatric surgery identifies a restricted set of inflammation- and extracellular matrix-related genes as pivotal in NASH and fibrosis pathogenesis | Sven Marcel Francque | Received |
THU-317 | N22 region based dot blot assay: an alternative to PCR for detection of Torque teno virus infection | Dhananjay Singh Mankotia | Received |
FRI-317 | Autologous hematopoietic stem cell transplantation into the liver: impact on hepatic macrophagic expansion and gene expression | Nicolas Lanthier | Received |
SAT-317 | Association of A313G polymorphism of GSTP1 gene with certain biochemical markers of liver injury, pro- and anti-inflammatory cytokines in patients with nonalcoholic fatty liver disease | Vasyl Prysyazhnyuk | Received |
THU-318 | NS3 inhibition coupled with potent direct acting antiviral combinations leads to enhanced hepatitis C virus specific immunity in hepatitis C virus-human immunodeficiency virus co-infected patients | Eleanor McKenna Pitt Wilson | Received |
THU-319 | Toll-like receptor 5 polymorphism at position c.1846T>C is associated with the development of hepatocellular carcinoma in caucasians with chronic hepatitis B infection | Janett Fischer | Received |
FRI-319 | Long-term disease progression in chronic hepatitis B Chinese patients with comorbid nonalcoholic fatty liver disease | Jian Gao Fan | Received |
SAT-319 | Non-alcoholic fatty liver disease – demographic features, risk factors and treatment practices across the Asia Pacific region – the GO ASIA initiative | Wah Kheong Chan | Received |
FRI-320 | Taste and appetite disorders in patients with non-alcoholic fatty liver disease | Joanna Musialik | Received |
SAT-320 | Blood-test based assessment of liver fibrosis, but not transient elastography, is less accurate in NAFLD patients of South Asian compared to White ethnicity | William Alazawi | Received |
SAT-321 | Periodontitis is strongly associated with NAFLD in the NHANES III cohort and in an independent prospective study, is more common in those with biopsy-proven advanced compared to mild liver disease | William Alazawi | Received |
THU-321 | TRAF1 as a marker of exhaustion during chronic hepatitis C | Elia Moreno | Received |
FRI-321 | Steatohepatitis: differential features on quantitative liver-spleen scan | John Carl Hoefs | Received |
FRI-322 | Vitamin D serum levels are only marginally lower in hepatic steatosis and do not correlate with Vitamin D dietary ingestion | Jorge Leitão | Received |
SAT-322 | Safety and pharmacokinetics of DUR-928 in patients with nonalcoholic steatohepatitis– a phase 1b study | William Kemp | Received |
SAT-323 | Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment | William Malcolm Rosenberg | Received |
FRI-323 | Hepatic steatosis in an adult population: stronger correlation with the presence of obesity and insulin resistance than with the dietary pattern. Results from a cross-sectional study | Jorge Leitão | Received |
FRI-324 | Evaluation of a novel nurse-led one-stop clinic for patients referred for investigation of suspected non-alcoholic fatty liver disease | Kirsty Fancey | Received |
SAT-324 | Comparison of risk factors for nonalcoholic steatohepatitis and advanced fibrosis between patients with obese and non-obese nonalcoholic fatty liver disease | Won Kim | Received |
THU-324 | No change in hepatitis C virus-specific T cell functionality after successful DAA treatment in chronic hepatitis C patients | Femke Stelma | Received |
THU-325 | Ki67, cyclin D and caspase 3 allow distinction of two sub-groups of alcoholic patients at early stages of alcoholic liver disease | Peter Stärkel | Received |
SAT-325 | Assessment of the hepatic steatosis using controlled attenuation parameter (CAP) measured with transient elastography in healthy population | Young Mi Hong | Received |
FRI-325 | High liver iron in biopsy of NAFLD patients is a predictor for cardiovascular and liver-related mortality | Elmar Aigner | Received |
FRI-326 | The COMMANDS study: improving community-based diagnosis and management of non-alcoholic fatty liver disease | Laura Burke | Received |
SAT-326 | Health-related quality of life in patients with non-alcoholic fatty liver disease | Yvonne Huber | Received |
SAT-327 | Non-alcoholic steatofibrosis is independently associated with both overall mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD) | Zobair M Younossi | Received |
FRI-327 | Effective dietary interventions for non-alcoholic fatty liver disease: barriers and facilitators to adoption of a Mediterranean diet in a northern European patient population | Laura Haigh | Received |
THU-327 | Development of a novel murine model of acute alcoholic hepatitis | Richard Wilkin | Received |
FRI-328 | Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: The Rotterdam Study | Louise Johanna Maria Alferink | Received |
SAT-328 | Can atherosclerotic cardiovascular risk score (ASCVD) predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)? | Zobair M Younossi | Received |
THU-328 | Evaluation of potential futility in alcoholic hepatitis – multicentre study | Rita Barosa | Received |
SAT-329 | Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development | Marica Meroni | Received |
FRI-329 | Severe histological liver phenotype of lean subjects with non-alcoholic fatty liver disease | Lukas Denkmayr | Received |
THU-329 | Clinical criteria are of limited value for diagnosis of alcoholic steatohepatitis | Rudolf E. Stauber | Received |
THU-330 | Drinking behaviour and rs738409:G in PNPLA3 are associated with slower recovery of liver function following severe alcoholic hepatitis | Stephen R Atkinson | Received |
FRI-330 | NAFLD as an indication for liver transplantation in the Nordic countries – a cohort study during 1982-2015 | Magnus Holmer | Received |
SAT-331 | Comparative effects of liraglutide, elafibranor and obeticholic acid on NAFLD activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed NASH | Michael Feigh | Received |
THU-331 | Low serum transferrin indicates short-term mortality in severe alcoholic hepatitis | Stephen Atkinson | Received |
FRI-331 | Effects of gene variants controlling vitamin D metabolism and serum levels on hepatic steatosis | Malgorzata Jamka | Received |
THU-332 | Serum procalcitonin correlates with baseline renal function and predicts mortality in severe alcoholic hepatitis | Stephen R Atkinson | Received |
SAT-332 | Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice | Mitchell Bijnen | Received |
FRI-333 | Exploring the patient perceived impact of non-alcoholic steatohepatitis | Maria-Magdalena Balp | Received |
FRI-334 | How often do we misclassify alcoholic as nonalcoholic fatty liver disease due the subjectivity in assessing alcohol consumption? | Mariana Verdelho Machado | Received |
SAT-334 | Ingestion of wheat amylase trypsin inhibitors promotes a proinflammatory liver and adipose tissue phenotype in diet induced non-alcoholic fatty liver disease in mice | Muhammad Ashfaq-Khan | Received |
THU-334 | Alcoholic hepatitis histological scores predict short-term survival in Asian patients with biopsy-proven alcoholic hepatitis | Won Kim | Received |
FRI-335 | Nonalcoholic fatty liver with hepatic arterial buffer response strongly caused metabolic diseases, while bright pancreas was not associated with metabolic diseases - 5 years´ cohort | Masashi Hirooka | Received |
THU-335 | Investigating immunomodulatory roles of CX3CR1 related with differentiation and functional polarization of kupffer cells | Young-Sun Lee | Received |
SAT-336 | Clinical course and outcome of pregnancy in women with non alcoholic fatty liver disease | Nasser Mousa | Received |
THU-336 | The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study | Ahmet Uygun | Received |
FRI-336 | Liver steatosis and fibrosis in at-risk European HIV-monoinfected patients | Maud Lemoine | Received |
FRI-337 | Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients | Maud Lemoine | Received |
SAT-337 | Neurobehavioral disturbances and hyperammonemia are evident in rodent model of NAFLD prior to cirrhosis stages | Natalia Arias | Received |
FRI-338 | Serologically assessed extracellular matrix remodeling is affected by bariatric surgery in morbidly obese NAFLD patients with 12 months follow-up | Mette Juul Nielsen | Received |
THU-338 | Trends in hospital charges and encounters for patients with nonalcoholic fatty liver disease compared to patients with alcohol related liver disease in the United States between 2005 and 2013 | Alexander Le Nguyen | Received |
SAT-339 | The effect of elafibranor and obeticholic acid on NAFLD Activity score and fibrosis stage in a novel metabolic rat model of diet-induced and biopsy-confirmed NASH | Niels Vrang | Received |
FRI-339 | First-in-Human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects | Bryan Laffitte | Received |
THU-339 | Liver-related mortality and morbidity of lean NAFLD is higher compared to overweight and obese NAFLD patients | Alexandra Feldman | Received |
SAT-340 | Precision-cut liver slices as an ex-vivo model for human NAFLD show hepatic progenitor cell activation and fibrogenesis | Olivier Govaere | Received |
FRI-340 | SAF score effectively identifies NAFLD subjects at high risk of subsequent liverrelated but not cardiovascular or malignancy-associated mortality and morbidity | Michael Strasser | Received |
THU-340 | Use of non-invasive methods to assess hepatic steatosis and advanced fibrosis in type-1 diabetic patients | Amandeep Singh | Received |
THU-341 | Prevalence of non–alcoholic fatty liver disease and advanced fibrosis in type - 2 diabetic patients via non-invasive methods | Naim Alkhouri | Received |
FRI-341 | An open-label randomized clinical study to compare the effects of a nutritional supplement versus vitamin E on fibroscan score in nonalcoholic steatohepatitis patients | Mohammad Shahed Ashraf | Received |
SAT-341 | miR-21 ablation and obeticholic acid ameliorate NASH in mice | Marta Bento Afonso | Received |
SAT-342 | Hepatic overexpression of chemerin attenuates expression of inflammatory and profibrotic genes in murine non-alcoholic steatohepatitis | Rebekka Pohl | Received |
THU-342 | Validation of non-invasive fibrosis assessments in biopsy-proven non-alcoholic fatty liver disease | Andreas Drolz | Received |
FRI-342 | The diagnostic accuracy of vibration controlled transient elastography for cirrhosis in subjects with nonalcoholic fatty liver disease | Mohammad Shadab Siddiqui | Received |
FRI-343 | Effect of a probiotic on fatty liver index and liver stiffness in NAFLD patients: randomized clinical trial | Natalia Bosak | Received |
FRI-344 | Changing eating behavior by motivational and controlled program during 12 weeks reduce weight, cytokeratin 18 levels and steatosis in patient with NAFLD | Nataliia Dynnyk | Received |
THU-345 | Individuation of presence and combination of genetic risk factors may help to refine the risk for most severe forms of NAFLD | Chiara Dell´Unto | Received |
FRI-345 | Influence of non-alcoholic fatty liver diease on the course of stable coronary heart disease | Iryna Igorivna Vakalyuk | Received |
FRI-346 | Role of a-ketoglutarate and ß-hydroxybutyrate in morbid obesity-associated non-alcoholic fatty liver disease: metabolomic approach | Noemí Cabré | Received |
SAT-346 | Prolonged-release pirfenidone is a dual activator for PPARalpha and PPARgamma and improves NASH features induced by high fat/carbohydrate diet | Roberto Rodriguez-Echevarria | Received |
SAT-347 | Steatogenic compounds induce triglyceride accumulation by multiple mechanisms in hepatocyte-like cells generated from human skin-derived precursors | Robim M Rodrigues | Received |
FRI-347 | PNPLA3, TM6SF2 and MBOAT7 genotypes and coronary artery disease | Nynke Simons | Received |
THU-347 | A new French paradox: morbidly obese patients with NASH have less bulimia than those without NASH | Clemence M Canivet | Received |
SAT-348 | The severity of portal inflammation is associated with hepatic fibrosis stage and components of metabolic syndrome in NAFLD | Sae Kyung Joo | Received |
THU-348 | Simple sugar consumption associated abnormal aminotransferase activity without intrahepatic fat: A cross sectional observational study | Dae Won Jun | Received |
THU-349 | Autonomic function is impaired across the spectrum of NAFLD | David Houghton | Received |
THU-350 | Cardiovascular risk factors are independent of fibrosis severity in NAFLD | Davide Roccarina | Received |
FRI-350 | Sprint interval exercise training reduces intrahepatic, visceral and subcutaneous abdominal fat despite no change in body weight, but has variable effects on whole-body insulin sensitivity | Jack Alistair Sargeant | Received |
FRI-351 | Hepatocyte nuclear factor 4a played a different role in lipotoxicity and bile acid toxicity in non-alcoholic fatty liver disease model | Jai Sun Lee | Received |
SAT-351 | Hepatotropic effects of granulocyte colony stimulating factor in non-alcoholic fatty liver disease: beyond marrow cell mobilization | Sang Bong Ahn | Received |
THU-351 | Estimation of serum "true collagen type III formation" (Pro-C3) levels as a marker of non-alcoholic steatohepatitis in a prospective cohort | Diana Julie Leeming | Received |
THU-352 | Nonalcoholic fatty liver disease and development of chronic kidney disease: a retrospective cohort study | Dong Hyun Sinn | Received |
SAT-352 | Role of group 2 innate lymphoid cells in the prevention of high-fat diet-induced nonalcoholic steatohepatitis by caffeine | Shuhei Hayashi | Received |
THU-353 | Metabolic and biochemical phenotypes can distinguish different patterns of histological severity in biopsy-proven NAFLD | Eduardo Vilar Gómez | Received |
FRI-353 | Serum cholesterol changes associated with NGM282 treatment in obese insulin resistant cynomolgus monkeys are reversed with either a statin or a PCSK9 inhibitor | Jian Luo | Received |
SAT-353 | Genetic polymorphism of PTPRD (rs35929428) and risk of non-alcoholic fatty liver disease in Japanese | Shunsuke Nakajima | Received |
THU-354 | Performance of the fibroscan and other noninvasive scales for detecting hepatic fibrosis in patients with nonalcoholic fatty liver disease | Esteban Saez | Received |
SAT-354 | Therapeutic effect of cerium oxide nanoparticles (CeO2NPs) in rats with diet-induced non-alcoholic steatohepatitis | Silvia Carvajal | Received |
FRI-354 | Elevated hepatic and adipose hepcidin expression in patients with advanced NAFLD fibrosis | John Denis Ryan | Received |
SAT-355 | Annexin A1 supplementation prevents the progression to fibrosis of nonalcoholic steatoepatitis (NASH) | Stefania Bruzzì | Received |
THU-355 | The role of dysbiosis in the development of non-alcoholic fatty liver disease in obese patients | Esther Nistal | Received |
THU-357 | Low vitamin D level is not associated with severity of non-alcoholic fatty liver disease in morbidly obese patients | Ana de Lourdes Candolo Martinelli | Received |
FRI-357 | Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mouse | Joost Willebrords | Received |
SAT-357 | Inhibition of IL6 trans-signaling leads to gut microbiota-dependant mature-onset obesity and metabolic syndrome | Eithan Galun | Received |
FRI-358 | Aramchol reduces established fibrosis in MCD diet animal model | José M Mato | Received |
SAT-358 | Adipose type I interferon signalling protects against metabolic dysfunction | Timon Adolph | Received |
THU-358 | Fasting serum bile acids profile and insulin resistance in healthy blood donors | Francesco Azzaroli | Received |
SAT-359 | CD103+ DCs are a key population in the progression of non-alcoholic steatohepatitis: could DCs represent a novel therapeutic application in NASH? | Veronika Lukacs-Kornek | Received |
THU-359 | Non-alcoholic fatty liver disease, hyperglycemia and overweight in the elderly: simple traveling companions or criminal conspiracy? | Giampaolo Bianchi | Received |
FRI-359 | New GLP-1 agonist dulaglutide improves metabolic dysfunction and extenuates development of non-acoholic steatohepatitis in mice | Katharina Luise Hupa | Received |
FRI-360 | Bone morphogenetic protein (BMP)-9 enhances high glucose-mediated vascular damage | Katja Breitkopf-Heinlein | Received |
THU-360 | Presence of metabolic syndrome and low CD4 count are independently associated with liver fibrosis in human immunodeficiency virus-infected patients with non-alcoholic fatty liver | Hugo Perazzo | Received |
SAT-360 | Altered methylation of FADS2 in NASH is partly explained by FADS2 genotypes | Jussi Pihlajamäki | Received |
SAT-361 | Receptor-interacting protein kinase 3 acts differently according to non-alcoholic fatty liver disease model | Waqar Khalid Saeed | Received |
THU-361 | Long term clinical implication of nonobese non-alcoholic fatty liver disease: comparison with metabolically abnormal but normal weight | Jae Youn Cheong | Received |
FRI-361 | M480, a novel non-bile acid FXR agonist, shows improvement across multiple parameters in a diet-induced obese mouse model with biopsy-confirmed NASH | Ken Song | Received |
FRI-362 | Increased non-shivering thermogenesis had preventive but no therapeutic effects on non-alcoholic steatohepatitis | Laurence Poekes | Received |
SAT-362 | Glucagon-like peptide-1 receptor agonists ameliorate inflammation and fibrosis in an optimized rodent NASH model via inhibition of inflammatory macrophage activation | Xiaoyu Wang | Received |
FRI-363 | EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis | Li-Juan Jiang | Received |
THU-363 | Allele frequency of non-alcoholic fatty liver disease-associated PNPLA3 and TM6SF2 polymorphism in a multi-ethnic population of 60,706 | Jake Peter Mann | Received |
THU-364 | Development and validation of automated assessment of liver fibrosis using second harmonic generation microscopy in patients with non-alcoholic fatty liver disease | Jason Chang | Received |
SAT-364 | High carbohydrate diet induces acute liver injury, enhanced de novo lipogenesis, inflammation and fibrosis but reversible by M2 macrophage polarization | Yong Ook Kim | Received |
FRI-364 | Extracellular vesicle changes in a diet induced model of non-alcoholic fatty liver disease progression and the role of TNF alpha | Linda A Ban | Received |
FRI-365 | Kupffer cell pool is maintained by local proliferation and the differentiation of bone marrow monocytes into short-lived monocyte-derived Kupffer cells during non-alcoholic steatohepatitis and recovery | Lindsey Devisscher | Received |
THU-365 | A pragmatic algorithm to rule out non-alcoholic steatohepatitis in patients at risk of non-alcoholic fatty liver disease in spite of a normal ultrasound | Javier Ampuero | Received |
SAT-365 | Exosome derived from palmitic acid-treated hepatocytes activates hepatic stellate cells | Young-Sun Lee | Received |
SAT-366 | Nano LC- mass spectrometry based proteomic profiling associated with significant fibrosis and collagen deposition in non-alcoholic fatty liver disease (NAFLD) | Zobair M Younossi | Received |
FRI-366 | STK25 is a critical determinant in nonalcoholic steatohepatitis | Margit Mahlapuu | Received |
FRI-367 | Survival analysis and response to ursodeoxycholic acid in patients with primary biliary cholangitis | Montserrat Garcia Retortillo | Received |
SAT-367 | Frequent deterioration in autoimmune hepatitis with acute presentation is not associated with acute AIH but acute exacerbation that could be differentiated from acute AIH by surrogate markers for liver fibrosis | Jong-Hon Kang | Received |
SAT-368 | The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time | Jorn C Goet | Received |
THU-368 | The anti-human immunodeficiency virus drug rilpivirine decreases hepatic injury in a nutritional model of non-alcoholic fatty liver disease through activation of the IL6/IL22-STAT3-p53 axis | Alberto Martí-Rodrigo | Received |
FRI-368 | The role of ethnicity in autoimmune hepatitis | Alessio Gerussi | Received |
THU-369 | Anti-fibrotic effect of NV556, a sanglifehrin-based cyclophilin inhibitor, in a preclinical model of non-alcoholic steatohepatitis | Alvar Grnberg | Received |
SAT-369 | Prognostic factors for transplant-free survival and external validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy | Ka Shing Cheung | Received |
THU-370 | Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids | Amalia Gastaldelli | Received |
SAT-370 | Clinical and translational outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease receiving vedolizumab | Kate Diana Williamson | Received |
FRI-370 | Evaluation of 6-thioguanine therapy in autoimmune hepatitis | Floris Frans van den Brand | Received |
SAT-371 | Enrichment of genetic variants in the glucocorticoid receptor signalling pathway in standard treatment failure autoimmune hepatitis | Peter Lykke Eriksen | Received |
THU-371 | Activation of miR-34a contributes to liver and muscle insulin resistance in experimental and human non-alcoholic fatty liver disease | Marta B. Afonso | Received |
FRI-371 | Evaluation of spleen length progression rate as a surrogate marker of clinical outcome in patients with primary sclerosing cholangitis | Franziska Jung | Received |
FRI-372 | Dysbiosis of the gut microbiota and increased gut permeability characterize secondary sclerosing cholangitis in critically ill patients (SSC-CIP) | Andreas Blesl | Received |
THU-372 | The immunomodulatory activity of the protease-inhibitor SerpinB3 in vivo and in vitro | Patrizia Pontisso | Received |
SAT-372 | Long-term outcomes in autoimmune hepatitis patients withdrawing from immunosuppressive therapy | Laura Harrison | Received |
SAT-373 | The interpretation of follow-up 3D-magnetic resonance cholangiopancreatography/magnetic resonance imaging in patients with primary sclerosing cholangitis is difficult and highly variable even between experienced specialists | Roman Zenouzi | Received |
THU-373 | Small molecule AXL inhibition prevents diet-induced liver fibrosis and inflammation in experimental models of NASH | Anna Tutusaus | Received |
FRI-373 | Intradermally applied LPA but not bile salts induce itch and pain in humans depending on the mode of application | Andreas E. Kremer | Received |
THU-374 | CD40 activation alleviates steatosis in cultured hepatocytes | Antonios Chatzigeorgiou | Received |
FRI-374 | Low platelet count influences the performance of the different biochemical criteria of ursodeoxycholic acid therapy response in primary biliary cholangitis | Anna Reig | Received |
SAT-374 | Analysis of shear wave elastography and serum autotaxin as novel non-invasive markers of liver fibrosis in patients with autoimmune hepatitis – a prospective study | Maciej K. Janik | Received |
SAT-375 | Health related quality of life (HRQoL) in patients with AIH: a prospective, single centre study | Maciej K. Janik | Received |
THU-375 | The PPARa-regulated dermatopontin is an important contributor to the liver fibrotic response in mouse models and has relevance to fibrosis progression in non-alcoholic fatty liver disease patients | Bart Staels | Received |
FRI-375 | The novel hexokinase 1 antibodies are useful for the diagnosis and associated with bad prognosis in primary biliary cholangitis | Anna Reig | Received |
FRI-376 | Primary biliary cholangitis demographics and outcomes: a paradigm shift | George Cholankeril | Received |
THU-376 | PBI-4050 reduces liver damage and fibrosis in a high-fat diet mouse model of obesity and metabolic syndrome | Brigitte Grouix | Received |
SAT-376 | A population based analysis of prevalence and treatment of autoimmune liver diseases in Germany | Marcial Sebode | Received |
THU-377 | A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis | Bryan C Fuchs | Received |
FRI-377 | Prompt initiation of intravenous corticosteroids prevents deterioration of acute/severe autoimmune hepatitis (AS-AIH) and the need for liver transplantation (LT) | George N Dalekos | Received |
SAT-377 | Dynamic risk prediction in Primary Biliary Cholangitis using the UK-PBC cohort | Marco Carbone | Received |
THU-378 | Development of LMB763, a novel, orally bioavailable, clinical farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis and hepatobiliary disorders | Bryan Laffitte | Received |
SAT-378 | Risk reduction with obeticholic acid in patients not achieving the POISE primary endpoint | Maren Harms | Received |
SAT-379 | Patient perspectives on living with autoimmune hepatitis - identifying opportunities to improve care | Margaret Corrigan | Received |
FRI-379 | The health burden of primary biliary cholangitis in Switzerland: a cross-sectional study | Benedetta Chiara Terziroli Beretta-Piccoli | Received |
THU-379 | Kupffer cell populations share inflammatory tasks and outline a shift in liver resident macrophage population during liver inflammation | Christina Mehrfeld | Received |
THU-380 | The gut microbiome of lean patients with non-alcoholic steatohepatitis: comparison with overweight/obese counterparts and healthy subjects, correlation with dietary intake and liver histology | Claudia P Oliveira | Received |
SAT-380 | Non-invasive evaluation of liver fibrosis in autoimmune hepatitis: still a challenge | Maria Lucia Cardoso Gomes Ferraz | Received |
FRI-380 | Increase in age at diagnosis of primary biliary cholangitis over the last 40 years | Carla Fiorella Murillo Perez | Received |
FRI-381 | NOD2 variants as novel genetic risk factors for secondary sclerosing cholangitis in critically ill patients | Christoph Jüngst | Received |
THU-381 | Influence of UCP3 gene polymorphisms on metabolic syndrome and cardiovascular risk in patients with in non-alcoholic fatty liver disease | Claudia P Oliveira | Received |
THU-382 | Anti-steatotic effects in conjunction with lowering of PNPLA3 mRNA exerted by LXR inverse agonists in human hepatocytes and in rodent models of non-alcoholic fatty liver disease | Claus Kremoser | Received |
SAT-382 | Early predictive factors of corticosteroids response in patients with severe/acute or fulminant autoimmune hepatitis | Anna Reig | Received |
SAT-383 | Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody positive subjects | Stephan Zandanell | Received |
FRI-383 | TNFa as therapeutic target in autoimmune hepatitis | Claudia S. Bovensiepen | Received |
FRI-384 | Development of a multivariate model using serum biomarkers to better define primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome | Henry H Nguyen | Received |
THU-384 | Role of the intestinal vitamin D receptor in obesity, adipose tissue inflammation and hepatic lipid accumulation | Daniel Jahn | Received |
THU-385 | NorUDCA improves liver injury and metabolic situation in mouse models of obesity and steatosis | Daniel Steinacher | Received |
SAT-385 | Tolerability and efficacy of 6-mercaptopurin in patients with autoimmune liver disease and azathioprine intolerance | Mayada Elnegouly | Received |
FRI-385 | Diagnosis of autoimmune sclerosing cholangitis in children with autoimmune hepatitis | Cristina Gonçalves | Received |
SAT-386 | The prognosis ability of GLOBE score in Chinese patients with primary biliary cholangitis | Zheyi Han | Received |
THU-386 | Protective effect of quercetin treatment on HFD-induced intestinal dysbiosis and barrier dysfunction in an in vivo model of non-alcoholic fatty liver disease | Francisco Jorquera | Received |
SAT-387 | Elevated baseline igg is a risk factor for on-treatment flares of autoimmune hepatitis in patients in biochemical remission | Neil Halliday | Received |
THU-387 | Mitochondrial-shaping proteins as specific biomarkers to distinguish alcohol from fat-induced liver toxicity | Elena Palma | Received |
THU-388 | Hypoxia-inducible factor 2alpha drives the progression of experimental non-alcoholic fatty liver disease by stimulating hepatocyte production of histidine rich glycoprotein | Elisabetta Morello | Received |
SAT-388 | Geoepidemiology, clinical manifestations and outcome of a large cohort of primary biliary cholangitis patients in Greece | Nikolaos K. Gatselis | Received |
FRI-388 | Autoimmune hepatitis with normal IgG levels at diagnosis: subtype with a higher rate of successful treatment withdrawal? | Johannes Hartl | Received |
FRI-389 | Twenty years´ single center experience with non-obstructive sinusoidal dilation | Dharma Budi Sunjaya | Received |
SAT-389 | Characteristics of Greek male patients with primary biliary cholangitis | Nikolaos K. Gatselis | Received |
THU-389 | Early increase in ammonia is a feature of non-alcoholic fatty liver disease and the ammonia lowering drug, ornithine phenylacetate (OCR-002) prevents progression of fibrosis in a rodent model | Francesco De Chiara | Received |
THU-390 | Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score | Francesco Valentini | Received |
SAT-390 | Incidence and prevalence of primary sclerosing cholangitis in a population-based cohort in Finland | Nina Barner-Rasmussen | Received |
FRI-390 | Stage of fibrosis and AST Platelet Ratio Index (APRI) as predictors of length of gestation in women with chronic liver disease | Enoka Gonsalkorala | Received |
FRI-391 | Autoimmune hepatitis in children and adults: a single centre experience | Lisa Perini | Received |
THU-391 | IVA337, a pan-ppar agonist, reduces non-alcoholic steatohepatitis feature and inhibits the inflammasome in murin models of non-alcoholic steatohepatitis | Guillaume Wettstein | Received |
SAT-392 | Cathepsin Z variants are associated with progression to end-stage hepatic failure in Japanese patients with primary biliary cholangitis | Nao Nishida | Received |
SAT-393 | T cell interactions with the biliary epithelium in primary biliary cholangitis | Rachel Emma Etherington | Received |
FRI-393 | Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease | David N. Assis | Received |
THU-393 | Liver iron concentration in patients referred for hyperferritinemia: multicenter analysis of the different groups according to HFE mutations and transferrin saturation index, prediction of liver iron overload in Southern Europe | Leire Zubiaurre | Received |
THU-394 | Genotypic-phenotypic profile of Wilson disease patients in Lebanon: Comparison with regional Arab countries | Aline Kamil El haddad | Received |
FRI-394 | Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating fecal bile acid composition and signaling | Claudia Daniela Fuchs | Received |
SAT-394 | Treg conditioning endows activated Teff with suppressor function in juvenile autoimmune liver disease | Rodrigo Liberal* | Received |
THU-395 | Liver iron overload within a UK based population by sex | Andrew G Mckay | Received |
FRI-395 | Autoimmune hepatitis patients with poor treatment response have a distinct liver transcriptome: implications for personalised therapy | Ben Millar | Received |
SAT-395 | The gut microbiota in liver transplanted primary sclerosing cholangitis patients is characterized by exacerbated dysbiosis | Johannes R. Hov | Received |
SAT-396 | miRNA-21-deficiency reduces liver injury, fibrosis and necroptosis in cholestatic bile duct-ligated mice | Marta Bento Afonso | Received |
FRI-396 | Obeticholic acid therapy improves cognitive decline in cholestatic liver disease | Ben Millar | Received |
THU-396 | Simultaneous non-invasive assessment of liver injury and body composition in alpha1-antitrypsin deficiency | Matthias C Reichert | Received |
SAT-397 | Impact of treatment with Telmisartan plus Propranolol on liver tight junctions in MDR2 -/- knockout mice | Sigrid Schulte | Received |
FRI-397 | A novel role for BMP9 as a negative regulator of oval cell-mediated regeneration in response to liver damage | Annalisa Addante | Received |
FRI-398 | Magnetic resonance imaging findings are related with serum and endoscopic markers of disease activity and severity in primary sclerosing cholangitis | Andrea Tenca | Received |
SAT-398 | Expression of the bile acid receptor TGR5 in livers of PSC patients and Mdr2-/- (Abcb4 -/-) mice | Maria Reich | Received |
THU-398 | Induced pluripotent stem cell-derived hepatocyte-like cells for study of the TTR protein quality control system | Christoph Niemietz | Received |
THU-399 | Dual proteotoxic stress promotes liver tumorigenesis via autophagy overload and activation of p62-mTOR-Nrf2 axis | Deniz Kuscuoglu | Received |
FRI-399 | Expression of the oncofetal marker Nope in the regenerating adult murine liver after disruption of interhepatocytic gap junctions with impaired polarisation via bile duct ligation | Andrea Bowe | Received |
FRI-400 | ACE2 therapy using a liver-specific AAV vector inhibits chronic biliary fibrosis in mice | Indu G Rajapaksha | Received |
THU-400 | Genetic variation of PNPLA3 and TM6SF2 associate with hepatocellular carcinoma in patients with alcohol-related cirrhosis | Felix Stickel | Received |
SAT-400 | Ablation of Notch-signaling via recombination signal binding protein for immunoglobulin kappa j region knockout in liver induces massive damage by impaired intra-hepatic bile duct morphogenesis, cholestasis and necrosis | Umesh Tharehalli Mathada | Received |
SAT-401 | Melatonin levels are significantly decreased in liver tissues of patients with primary biliary cholangitis | Urszula Wasik | Received |
THU-401 | A novel algorithm for the management of patients with PiZZ alpha-1 antitrypsin deficiency | Grace Dolman | Received |
THU-402 | Soluble (s)CD163 a macrophage activation marker is associated with liver disease severity in patients with Wilson´s disease | Henning Groenbaek | Received |
SAT-402 | MicroRNA expression profiling of peripheral blood B cells from patients with distinct pathologicalstages of primary biliary cirrhosis | Xiaomei Wang | Received |
FRI-402 | Pediatric autoimmune hepatitis shows a strong increase of intrahepatic Tregs and an IL-2 associated Treg decline under therapy | Jana Diestelhorst | Received |
SAT-403 | Identification of Twinfilin-1 as a key regulator of cholangiocyte biological response to injury: evidence for a possible role of ageing in the progression of cholangiopathies | Luca Maroni | Received |
THU-403 | Assessment of bile salt export pump (BSEP) inhibition by BSEP-reactive immunoglobulins from Antibody-induced BSEP deficiency patients using a novel, cell-based assay | Jan Stindt | Received |
FRI-403 | Circulating fibroblast growth factor 19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis | Jian Luo | Received |
THU-404 | Macrophage activation in patients with wilsons disease – associations with metabolic liver function, liver disease severity and fibrosis | Jessica Almida Ellinor Björklund | Received |
SAT-404 | Exploring the role of macrophages in primary sclerosing cholangitis | Yung-Yi Chen | Received |
FRI-404 | Exhaustive blood immune phenotype of patients with autoimmune hepatitis | Amédée Pablo Renand | Received |
SAT-405 | Dysregulated bile salt homeostasis in patients with chronic intestinal failure on home parenteral nutrition | Kiran V.K. Koelfat | Received |
THU-405 | Transcriptomic analysis reveals novel insights into the effect of therapeutic venesection in HFE haemochromatosis | John Denis Ryan | Received |
THU-406 | Elevated faecal free iron content in HFE haemochromatosis is reduced by therapeutic venesection | John Denis Ryan | Received |
SAT-406 | Bacterial translocation after liver transplantation is associated with biliary complications | Jasmijn Wieke Selten | Received |
FRI-406 | A protective role of IL-22BP in acute liver injury | Anastasios D. Giannou | Received |
FRI-407 | Neutrophil-to-lymphocyte ratio as an independent predictor of mortality in critically ill cirrhotic patients | Caroline Lemaitre | Received |
THU-407 | Multi-center study of liver disease in alpha1-antitrypsin deficiency: non-invasive evaluation of liver fibrosis in homozygous PiZZ patients | Karim Hamesch | Received |
SAT-407 | Plasma expansion is key for sustained liver function and viability during normothermic and subnormothermic ex vivo machine perfusion in a rat model | Joseph Maria George Gassner | Received |
THU-408 | Heterozygous carriage of the alpha1-antitrypsin Z variant rs28929474 predisposes to the development of cirrhosis in the presence of alcohol misuse and non-alcohol-related fatty liver disease | Karim Hamesch | Received |
FRI-408 | Etiology, outcome and predictors of mortality of viral related acute liver failure: a single centre prospective cohort study | Chetan Ramesh Kalal | Received |
SAT-408 | Upregulation of MATE-1 transporter by obeticholic acid correlates with increased biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury | Laura Giuseppina Di Pasqua | Received |
FRI-409 | Combining renewable human liver tissue and novel extracorporeal devices to deliver mammalian liver support | David Hay | Received |
FRI-410 | Tapered steroid treatment leads to distinct ALT response patterns in patients with acute severe hepatitis, and may help to distinguish AIH from DILI | Elisabeth Mohr | Received |
THU-410 | GANAB mutations: a possible lead to a common hepatic cystogenesis pathway in autosomal dominant polycystic kidney and liver disease? | Liyanne Francisca Maria Van De Laarschot | Received |
SAT-410 | MiRNA 181a and 148a plasma levels during acute cellular rejection in liver transplantation | Pablo Ruiz | Received |
SAT-411 | Amplification of long noncoding RNA OTUD7AP1, targeted by miRNA 125b, promotes proliferation in hepatocellular carcinoma | Ping Chen | Received |
THU-411 | Whole genome sequencing analysis of familial primary sclerosing cholangitis | Magdalena Budzinska | Received |
FRI-411 | Liver progenitors and hematopoietic stem cells in acute liver failure and cirrhosis | Estela Solanas | Received |
FRI-412 | The Role of chemokine (C-C motif) ligand 2 and the diet influence in the energy metabolism | Fedra Luciano | Received |
SAT-412 | Impaired liver regeneration following hepatectomy and bleeding is associated with a shift from hepatocyte proliferation to hypertrophy | Rinat Abramovitch | Received |
THU-413 | New molecular classification of hepatoblastoma through an integrative genomic and transcriptomic study | Marina Simon-Coma | Received |
FRI-413 | Human hepatobiliary progenitor cells as new candidates for liver cell therapy | Giuseppe Mazza | Received |
FRI-414 | IL-33 protects Murine viral fulminant hepatitis by targeting coagulation hallmark protein Fgl2/Fibroleukin expression | Haijing Yu | Received |
THU-414 | Variants in TM6SF2 and PCSK7 are risk factors for the development of cirrhosis in people with genetic haemochromatosis | Marsha Y Morgan | Received |
SAT-414 | Donation mode impacts on invariant natural killer T cell population leading to scarce iNKT cells in donation after cardiac death liver grafts despite a significant increase in B cells and CD1d expression | Yasmeen Giuma Ghnewa | Received |
SAT-415 | The nucleoprotein High-mobility group box 1 critically regulates the immune response to bacterial infection | Annika Volmari | Received |
THU-415 | Inherited prothrombotic risk factors in children with extrahepatic portal vein obstruction: a case-control study | Massimo Primignani | Received |
THU-416 | Association between GNPAT genotypes and serum iron parameters in C282Y homozygous and C282Y/H63D compound heterozygous patients | Moritz Tobiasch | Received |
FRI-416 | Augmenter of liver regeneration protects against carbon tetrachloride-induced liver injury by promoting the autophagy in mice | Hongbo Shi | Received |
SAT-417 | Characterisation of cell-type-specific responses in the liver towards IL-1ß by a mathematical model for the p38MAPK/MK2 pathway | Stephanie Wolf | Received |
FRI-417 | Formation of bile canaliculi in liver progenitor cell-derived hepatocytes determines clinical outcome of acute-on-chronic liver failure | Xiaodong Yuan | Received |
THU-417 | Antibiotics induce remission in pediatric PSC-AIH overlap syndrome allowing corticosteroid-free therapy | Pauline Sambon | Received |
FRI-418 | Evaluation of spheroid reservoir bioartificial liver with porcine hepatocytes in rhesus monkey model of acute liver failure | Ji Bao | Received |
THU-418 | Clinical outcomes in polycystic liver disease comparing autosomal dominant polycystic liver disease with autosomal polycystic kidney disease: results of the PLD registry | Rene Van Aerts | Received |
THU-419 | GMP-level isolation, quality assessment and biosafety distribution evaluation on human amnion epithelial cell for cell-based therapies | Roberto Gramignoli | Received |
SAT-419 | GW4064 alleviate mitochondrial dysfunction and intestinal epithelial cell apoptosis through farnesoid X receptor protected lipopolysaccharides-induced acute intestinal inflammation | Hsuan Miao Liu | Received |
FRI-419 | The hepatoprotective cytokine Cardiotrophin-1 (CT-1) attenuates inflammation and prevents the systemic effects of endotoxemia by promoting M2 macrophage polarization | Jose Miguel Vélez-Ortiz | Received |
THU-420 | Identification of Src tyrosine kinase as a therapeutic target in cystic fibrosis liver disease using patient specific induced pluripotent stem cells -derived cholangiocytes | Romina Fiorotto | Received |
SAT-421 | Impact of sex and apolipoproteins on macrophage activation and Entamoeba histolytica induced liver damage | Jill Noll | Received |
FRI-421 | Acute on chronic liver failure (ACLF ) – combining CLIF-SOFA criteria with APASL definition of ACLF enhances prediction of mortality at 1, 3 and 6 months | Krishnadas Devadas | Received |
FRI-422 | Development of human liver extracellular matrix hydrogel for three dimensional cell culture and cell transplantation | Luca Frenguelli | Received |
THU-422 | Fontan-associated liver disease: diagnosis by elastography and laparoscopic liver biopsy | Yohei Koizumi | Received |
SAT-422 | Involvement of TA and ?N p63 and p73 isoforms on the regulation of cell death and tumour recurrence in patients with hepatocarcinoma submitted to liver transplantation | Jordi Muntané | Received |
FRI-423 | Exacerbated LPS/GalN-induced liver injury in the stress sensitive Wistar Kyoto rat: possible role of the endocannabinoid system? | Marykate Killilea | Received |
SAT-423 | Hepatitis B virus infected cell slows down its cell cycle and proliferation by viral protein and replication | Kenichi Morikawa | Received |
THU-423 | Prognostic value and prediction of extra-tumoral microvascular invasion among patients who candidate for hepatectomy or liver transplantation for hepatocellular carcinoma | Hidetoshi Nitta | Received |
FRI-424 | Long term mortality is increased in patients surviving acute liver failure without liver transplantation | Mhairi C Donnelly | Received |
THU-424 | Ischaemic-reperfusion injury and different risk factors for acute kidney injury in donation after circulatory death liver transplantation. UK single centre study | Ilaria Umbro | Received |
SAT-424 | EZH2 methyltransferase and JMJD3/UTX demethylases are involved in hepatocytic differentiation and liver cancer cells plasticity | Laura Belloni | Received |
FRI-425 | Genetic ablation of pannexin1 protects against acetaminophen-induced hepatotoxicity in mice | Michaël Maes | Received |
SAT-425 | SLU7 is a survival factor for cancer cells working as a mitotic regulator | Maddalen Jimenez | Received |
FRI-426 | Hepatocyte-specific deletion of type I interleukin-1 receptor (IL-1RI) attenuates D-GalN/LPS-induced acute liver injury in vivo | Nadine Gehrke | Received |
SAT-426 | p38-alpha MAPK couples inflammatory response and proliferation of hepatocytes during acute liver injury | Manon Fortier | Received |
THU-426 | Long term prevention of recurrent hepatitis B after liver transplantation using nucleos(t)ide analogs after HBIg discontinuation | James Vu | Received |
THU-427 | No increase in graft fibrosis for hepatitis B surface antigen positive patients after liver transplantation using entecavir monotherapy | James Yan Yue Fung | Received |
SAT-427 | Amino-functionalized nanoparticles as a platform for mTOR activity modulation in hepatocellular carcinoma Huh7 cell line | Mariia Lunova | Received |
FRI-427 | Melatonin protects liver in experimental severe acute liver failure | Norma Anair Possa Marroni | Received |
FRI-428 | Hepatic accumulation and activation of CD8+ T cells aggravate acute liver injury | Patricia Maria Niemietz | Received |
THU-428 | Pregnancy outcomes in the post liver transplant setting: The Irish experience | Jayne Doherty | Received |
THU-429 | Sarcopenia is associated with increased hospital expenditure in patients undergoing major cancer surgery of the alimentary tract | Jeroen Van Vugt | Received |
SAT-429 | Reduced miR-26b-5p expression imparts malignant features and help in EpCAM+ liver cancer stem-like cells maintenance via heat shock cognate 71kDa protein (HSC71/HSPA8) | Ritu Khosla | Received |
SAT-430 | Implications of Unc5A depletion for hepatocyte survival in chronic liver diseases upon induction of the unfolded protein response | Romain Barnault | Received |
FRI-430 | Experimental approach to IGF-1 therapy in acute liver damage: acute injury by carbon tetrachloride in controls and mice with partial IGF-1 deficiency | Rocío García de la Garza | Received |
THU-430 | Progression of familial amyloidosis after domino liver transplantation in donor and recipient | Johanna Vollmar | Received |
FRI-431 | CX3CR1 modulates the differentiation of monocyte-derived inflammatory dendritic cells in response to hepatic injury | Stefania Bruzzi | Received |
THU-431 | Clinical outcomes of patients delisted from the waiting list of liver transplantation after interferon-free antiviral therapy | Juan Manuel Pascasio | Received |
THU-432 | Donor mannose-binding lectingene polymorphisms increase the risk of severe bacterial infections after liver transplantation | Julissa Lombardo | Received |
FRI-432 | External validation of the USALFSG acute liver failure outcome prediction criteria | William Bernal | Received |
SAT-432 | Microphysiological systems for studying interactions between the liver, gut and immune system | Tomasz Kostrzewski | Received |
SAT-433 | Combined targeting of cholangiocytes and activated stromal cells with a BH3 mimetic ameliorates fibrosis in a mouse model of PSC | Anja Moncsek | Received |
THU-433 | Pregnancy outcomes in liver transplant recipients: a single tertiary centre experience | Katherine Johanna Arndtz | Received |
FRI-433 | The role of bacterial infection (BI) in decompensated cirrhosis patients with or without acute-on-chronic liver failure (ACLF) | Zhujun Cao | Received |
FRI-434 | NOX4 dependent activation of hepatic stellate cells with conditioned medium derived from Isoniazid treated hepatocytes: an In-vitro study | Abhijit Chowdhury | Received |
SAT-434 | Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling | Benedicte Delire | Received |
THU-434 | Effect of diabetes and obesity on short-term outcome after major liver resection | Katrin Hoffmann | Received |
SAT-435 | The dynamic roles of hepatocyte and leukocyte-specific CD147 in a progressive liver injury mouse model | Christine Yee | Received |
THU-435 | Occult Hepatitis B Virus persistence in liver transplant recipients despite prophylactic hepatitis B immune globulin and potent nucleos/tide analogues therapy | Keith CK Lau | Received |
FRI-435 | Alpha toocotrienol causes apoptosis of activated hepatic stelate cells through lysosome mitochondrial axis in INH induced liver fibrosis: an in-vitro study | Abhijit Chowdhury | Received |
FRI-436 | TAK1 signaling is essential for NLRP3 activation in mouse drug-induced damage-associated hepatitis | Bibo Ke | Received |
SAT-436 | Comparison of liver injury evolution in mouse models | Christine Yee | Received |
THU-436 | A pospective study to evaluate the impact of early everolimus on the recurrence of hepatocellular carcinoma after liver transplantation | Manuel Rodríguez-Perálvarez | Received |
SAT-437 | CD5L modulates primary human hepatic stellate cells activation | Cristina Barcena | Received |
THU-437 | Impact of "rescue allocated" livers on outcomes after liver transplantation: a propensity score matching analysis | Mara Disabato | Received |
FRI-437 | The novel macrophage activation marker soluble Mannose Receptor, and soluble CD163, are elevated after acetaminophen intoxication in relation to liver disease severity | Cecilie Brøckner Siggaard | Received |
THU-438 | Medical emergency team activation in patients pre- and post-liver transplantation is associated with prolonged length of stay and higher morbidity | Marcus Robertson | Received |
SAT-438 | Induced pluripotent stem cells-derived extracellular vesicles shuttle bioactive molecules with anti-fibrotic potential in vitro and in vivo | Davide Povero | Received |
FRI-438 | Characterisation of the immune response in patients with drug induced liver injury | Giacomo Germani | Received |
SAT-439 | The vacuolar adenosine tri-phosphatase (v-ATPase) proton pump as therapeutic target in human activated HSC | Giusi Marrone | Received |
THU-439 | Interferon-free therapy is effective and safe for hepatitis C recurrence in liver transplant hepatitis C virus/human immunodeficiency virus coinfected recipients: A case-control study | Xavier Forns | Received |
FRI-439 | Drug-induced effects on mtDNA homeostasis in HepaRG cells and modulation by steatosis | Dounia Le Guillou | Received |
FRI-440 | p62/sqstm1 in a drug-induced model of hepatotoxicity: a novel role beyond autophagy | Fernando Alegre | Received |
THU-440 | The golden hour: length of total warm ischemia time presages development of severe acute kidney injury after DCD liver transplantation | Marit Kalisvaart | Received |
SAT-440 | Kahweol attenuates hepatic fibrosis by inhibition of CTGF via TGF-ß signaling pathways | Byoung Kuk Jang | Received |
SAT-441 | Non-sense mediated RNA decay regulates the unfolded protein response during hepatic stellate cell activation | Inge Mannaerts | Received |
THU-441 | The use of prophylactic strategies using hepatitis B immunoglobulin for hepatitis B recurrence after liver transplantation in routine clinical practice in Spain. preliminary results of the 1st round of a delphi panel | Martín Prieto | Received |
FRI-441 | The S-ademetionine role in the prevention of liver injury in patients with acute leukemias in the polychemotherapy dynamics | Igor Skrypnyk | Received |
FRI-442 | Reprogramming of human umbilical cord-derived mesenchymal stromal cells into hepatocyte-like cells by over-expression of hepatocyte nuclear factor 1-alpha | Karolien Buyl | Received |
THU-442 | Entecavir or tenofovir monotherapy prevents hepatitis B virus recurrence in liver transplant recipients: a 5-year follow-up study after hepatitis B immunoglobulin withdrawal | Matteo Angelo Manini | Received |
SAT-442 | Local environment in cirrhotic liver induces Th2 polarization of CD4+ cells which amplify fibrogenesis by activating hepatic stellate cells | Johanna Antonia Reissing | Received |
SAT-443 | Ammonia elevates B-neurexin in hepatic stellate cells to escape NK cells activity | Johnny Amer | Received |
THU-443 | The incidence of metabolic syndrome and the association with its clinical consequences after liver transplantation | Milou Mireille Ter Avest | Received |
FRI-443 | Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity in mice | Kengo Tomita | Received |
FRI-444 | Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry | Raùl J Andrade | Received |
THU-444 | Differences in the occurrence of metabolic syndrome between patients treated with a calcineurin inhibitor and patients treated with an mTOR inhibitor after liver transplantation | Milou Mireille Ter Avest | Received |
SAT-444 | Genome wide methylation profile of liver from patients with severe hepatic fibrosis related to HCV infection | Luydson Vasconcelos | Received |
SAT-445 | Autophagy regulates endothelial dysfunction and hepatic fibrosis development | Maria Ruart | Received |
FRI-445 | Prevalence and severity of liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients | Antonio Grieco | Received |
FRI-446 | Jnk2 is indispensable in murine and human Ibuprofen-induced acute liver failure | Miguel Eugenio Zoubek | Received |
THU-446 | The association of the metabolic syndrome with cardiovascular and cerebrovascular outcomes and renal dysfunction after liver transplantation | Olivia FH Ho | Received |
SAT-446 | How gender influences fibrosis regression in a chronic murine model of hepatic injury | Marika Crescenzi | Received |
SAT-447 | Activated primary stellate cells show decreased aquaporin 3 expression in parallel with cellular senescence which is restored with PPAR-? agonist establishing quiescence | Matteo Tardelli | Received |
THU-447 | Impact of hepatitis C virus treatment on renal function in liver transplant patients | Omar Massoud | Received |
FRI-447 | Development of a novel 3D organotypic human HepaRG-based non-invasive imaging platform for pre-clinical drug screening | Nicole Jenna Martucci | Received |
SAT-448 | Differential role of NLRP3 inflammasome during acute and chronic cholestatic liver injury | Mick Frissen | Received |
THU-449 | Preoperative von willebrand factor - antigen predicts clinical outcome after liver resection: a prospective, international, multicenter trial | Patrick Starlinger | Received |
FRI-449 | Drug-induced liver injury: presentations, causes and outcomes: an Egyptian study | Omkolthoum Alhadad | Received |
THU-450 | Nurse-led self-management support across two hospitals in liver transplantation: a win-win situation for patients and health care professionals | Patrizia Künzler-Heule | Received |
SAT-450 | Immunofluorescence identifies distinct subsets of endothelial cells in the human liver | Otto Strauss | Received |
FRI-450 | Influence of host characteristics and pharmacological properties on type of liver injury in hepatotoxicity | Raul Andrade | Received |
FRI-451 | Liver progenitor cells significantly contribute to hepatocyte pool in chronic liver injury and cirrhosis: a kinetic study in mice | Rita Manco | Received |
THU-451 | History of marijuana use does not affect outcomes on the liver transplant waitlist | Prashant Kotwani | Received |
SAT-451 | Inhibition of canonical WNT signaling pathway by ß-catenin/CBP inhibitor ICG001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12 | Ruchi Bansal | Received |
FRI-452 | Benzo[a]pyrene and ethanol exert a high toxicity potential in steatotic HepaRG cells: possible role of low NDUFA4L2 expression | Simon Bucher | Received |
SAT-452 | Antifibrotic effects of 8-hydroxydeoxyguanosine through the inhibition of NADPH oxidase-derived oxidative stress in vitro and in vivo model of liver fibrosis | Seung Kak Shin | Received |
THU-452 | The effect of beta-hydroxy-beta-methyl butyrate supplementation on muscle wasting in patients undergoing liver transplantation: results of preliminary analysis | Rosanna Lacetera | Received |
THU-453 | Hyperfibrinolysis during liver transplantation detected by classical parameters and thromboelastometry | Sara Maggiolo | Received |
FRI-453 | Modelling the impact of targeted interventions on the HCV epidemic in Pakistan: the road to HCV elimination | Aaron G. Lim | Received |
FRI-454 | The evaluation of homelessness on HCV treatment outcomes among current and former people who inject drugs | Arshia | Received |
SAT-454 | The anti Fibrotic effect of Aramchol on liver Fibrosis in TAA animal model | Shimon Reif | Received |
SAT-455 | A novel 3D Liver Microtissue Model for studying steatosis in vitro | Simon Messner | Received |
THU-455 | Implementation of psycho-social electronically-captured patient-reported outcome measures for liver transplant at Mayo Clinic Florida | Shehzad Khan Niazi | Received |
FRI-455 | Pilot validation study of a rapid test in oral fluid for population screening of hepatitis C virus infection | Carmina Pallarés | Received |
FRI-456 | Rapid and large implementation of HCV treatment advances in France, 2007-2015 | Christine SILVAIN | Received |
SAT-456 | In bone marrow derived macrophages hepatocyte trigger a marker pattern that is indicative for alternatively activated, regulatory type macrophages | Stephanie Wolf | Received |
THU-456 | MELD score > 19 on day five after liver transplant in hepatitis C virus-positive recipients: impact on 90-day graft loss and analysis of predictors | Silvia Martini | Received |
SAT-457 | FOXA2 overexpressed adipose derived stem cells attenuated acute liver injury model | Yeon Ji Chae | Received |
THU-457 | Favourable virological and clinical outcomes at 1 year after liver transplantation in hepatitis C virus-positive patients who received direct-acting antivirals on the waiting list | Silvia Strona | Received |
FRI-457 | Screening for HCV in pregnant women and their partners | Charlotta Millbourn | Received |
THU-458 | Risk of late-onset CMV infection after liver transplantation is associated with recipient´s IFNL4 rs12979860 genotype | Sona Franková | Received |
SAT-458 | Dabigatran reduces liver fibrosis in thioacetamide-injured rats | Yun-Cheng Hsieh | Received |
SAT-459 | A novel FXR agonist EDP-305 potently suppresses liver injury and fibrosis in mouse models of biliary and metabolic liver disease | Yury Popov | Received |
THU-459 | Evolution of body weight parameters up to 3 years after liver transplantation: the prospective Swiss transplant cohort study | Sonja Beckmann | Received |
THU-460 | Liver transplantation does not impact the renal function outcome in Alagille syndrome | Tanguy Demaret | Received |
FRI-460 | HCV elimination among people who inject drugs. What would happen after the WHO HCV elimination target is achieved? | Ilias Gountas | Received |
SAT-460 | Morphology based assessment of liver fibrosis using a new quantitative metric in abdominal CT scans | Andreas Christe | Received |
FRI-461 | Treatment and primary prevention in people who inject drugs (PWID) for chronic Hepatitis C (CHC): Is elimination possible in a high prevalence setting? | Ilias Gountas | Received |
THU-461 | The risk of death after liver transplantation due to increasing donor age is highest in young recipients | Therese Bittermann | Received |
SAT-461 | Soluble CD147 has an altered expression profile with liver disease progression and in different ethnicities | Aimei Lee | Received |
SAT-462 | Non invasive diagnostic modalities to predict advanced hepatic fibrosis in patients with non alcoholic fatty liver disease: a retrospective study | Ajeet Singh Bhadoria | Received |
FRI-462 | The impact of broader hepatitis C treatment strategies on population health and social value in England | Alison Silverstein | Received |
THU-462 | The burden of healthcare utilization after liver transplantation and its relationship with pre-transplant hospitalization | Therese Bittermann | Received |
FRI-463 | Integrating voluntary hepatitis B, C and HIV screening in the compulsory tuberculosis entry screening for immigrants, The Netherlands: a pilot project | Janneke Bil | Received |
SAT-463 | Risk of liver fibrosis in patients with Thalasemia major; a tertiary center experience | Alghalya A Alomairi | Received |
THU-463 | Recurrence of primary sclerosing cholangitis is associated with lower survival after liver transplantation: an analysis of the European liver transplant registry data base | Thijmen Visseren | Received |
SAT-464 | Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis | Alina M. Allen | Received |
FRI-464 | Access to hepatitis C treatment in Europe: findings from the 2016 Hep-CORE study | Jeffrey Victor Lazarus | Received |
THU-465 | A glycomic serum marker analysed at one week after liver transplantation is an independent predictor of graft loss during the first year after liver transplantation | Xavier Verhelst | Received |
FRI-465 | Do elevated liver values necessarily indicate a health problem or could poorly defined upper limits of normal be an issue? Alanine aminotransferase and gamma-glutamyltransferase depend strongly on age | Johannes Wiegand | Received |
SAT-465 | Acoustic Radiation Force Imaging the Fontan liver – feasibility and reproducibility | Amanda J Nicoll | Received |
THU-466 | Pretransplant glycomic analysis of perfusate is predictive of primary non function after liver transplantation | Xavier Verhelst | Received |
SAT-466 | The clinical utility of non-invasive tests in cirrhosis: results of decision analysis modelling | Avik Majumdar | Received |
FRI-466 | Hepcheck Dublin: homeless, hepatitis C & competing priorities | John S Lambert | Received |
FRI-467 | Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia | Julie Bouscaillou | Received |
SAT-467 | Prevalence of fatty liver and fibrosis in patients with type 2 diabetes mellitus and previously undetected liver disease as assessed by transient elastography and ultrasound | Ivica Grgurevic | Received |
THU-467 | Inhibition of NADPH oxidase-2 and P38 mitogen activated protein kinase suppresses acrolein aggravated hepatic ischemia reperfusion injury through neutrophil extracellular traps | Arumugam Suyavaran | Received |
SAT-468 | Non-invasive detection of patients with nonalcoholic steatohepatitis at risk of adverse liver outcomes | Jagpreet Chhatwal | Received |
FRI-468 | Smoking and metabolic syndrome components are independent predictors of mortality in patients with chronic liver disease in the United States | Karn Wijarnpreecha | Received |
SAT-469 | ECV-associated miRNA levels as non-invasive biomarkers for early-stage HBV/HCV-induced liver fibrosis | Joeri Lambrecht | Received |
THU-469 | Herpesviruses in bile: Increasing sensitivity by testing the right compartment | Conrad Rauber | Received |
FRI-469 | Chronic hepatitis C diagnosis increases sick leave and disability pension | Jonas Söderholm | Received |
THU-470 | Simulated microgravity significantly impacts the differentiation and metabolism of human hepatic and biliary tree stem/progenitor cells | Daniele Costantini | Received |
FRI-470 | Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians | Mahmud Mahamid | Received |
SAT-470 | Non-invasive fibrosis markers are independent predictors of mortality among U.S. adults with nonalcoholic fatty liver disease | Karn Wijarnpreecha | Received |
SAT-471 | Association between non-invasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease in the United States | Karn Wijarnpreecha | Received |
THU-471 | The role of recipient epithelial cells in regeneration after liver transplantation: different kinetics of chimerism for hepatocytes and bile duct epithelial cells | Floris Johan Maria Roos | Received |
FRI-471 | A survey on non-alcoholic fatty liver disease amongst general practitioners: time to bridge the gap between hepatologists and primary care | Jef Verbeek | Received |
FRI-472 | Identification of the healthy ranges for enhanced liver fibrosis score | Agostino Colli | Received |
THU-472 | Approaches to fabricate practical recellularized liver graft using primary liver cells-our seeding method for optimal distribution of parenchymal and endothelial cells | Hidenobu Kojima | Received |
SAT-472 | Non-invasive evaluation of clinically significant portal hypertension: validation of two novel algorithms combining liver and spleen stiffness using shear-wave elastography in a large independent cohort of patients with cirrhosis | Laure Elkrief | Received |
SAT-473 | Elastogram quality assessment score in vibration controlled transient elastography: diagnostic performance compared to digital morphometric analysis of liver biopsy | Leandro Cesar Mendes | Received |
FRI-473 | Non-steroid anti-inflammatory drugs for biliary colic | Mirella Fraquelli | Received |
THU-473 | Human leukocyte antigen matching in living donor liver transplantation: does it affects the outcome? | Iman Montasser | Received |
SAT-474 | Ultrasound-measured visceral adipose tissue correlates with risk factors, severity and co-morbidities of NAFLD better than waist circumference | Lucia Napoli | Received |
THU-474 | Bile duct strictures after liver transplantation are associated with a donor glypican-6 polymorphism linked to the biliary stem cell niche | Jasmijn W. Selten | Received |
FRI-474 | Hepatitis prevention, control, and elimination program in Mongolia: National hepatitis elimination program in a country with the highest burden of viral hepatitis in the world | Naranbaatar Dashdorj | Received |
FRI-475 | Reaching hepatitis C virus elimination targets in Australia requires use of complementary cost-effective interventions along the care cascade | Joseph Doyle | Received |
SAT-475 | Controlled attenuation parameter predicts steatosis in alcoholic liver disease and correlates with poor metabolic phenotype and cardiovascular risk: A biopsy-controlled multicenter study | Maja Thiele | Received |
THU-475 | The non-alcoholic fatty liver disease liver fat score is associated with liver disease mortality in the United States population | Aynur Unalp-Arida | Received |
SAT-476 | Transient elastography correlates with liver fibrosis and markers of portal hypertension in PSC: Laennec score-based analysis of explanted livers | Marcin Krawczyk | Received |
FRI-476 | Eliminating hepatitis C virus from HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour | Joseph Doyle | Received |
THU-476 | The impact of bariatric surgery on nonalcoholic fatty liver disease and cardiovascular risk utilizing non-invasive measures | Carmit Netanel | Received |
THU-477 | Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease | Caussy Cyrielle | Received |
FRI-477 | Implementing the WHO Global Health Sector Strategy on Viral Hepatitis in Denmark – modeling the effects of community-based care on the elimination of HCV by 2030 | Ole Henriksen | Received |
SAT-477 | Effect of meal ingestion on liver stiffness and controlled attenuation parameter | Marco Silva | Received |
FRI-478 | An alternative screening strategy for hepatitis C virus infection among americans not belonging in the baby boomer birth cohort | Prowpanga Udompap | Received |
THU-478 | Noninvasive diagnosis of hepatic fibrosis by biofibroscore in patients with chronic hepatitis C virus infection | Chen-Hua Liu | Received |
SAT-478 | Dynamics of liver stiffness and serum IP10 levels among patients with chronic hepatitis C who achieved SVR with DAA treatment | Cristina Rigamonti | Received |
SAT-479 | Predictors of persistence of clinical significant portal hypertension in patients with HCV liver cirrhosis following 3D therapy and SVR | Maria C. Speranta Iacob | Received |
THU-479 | Screening for nonalcoholic fatty liver disease by transient elastography with controlled attenuation parameter in unselected patients with inflammatory bowel disease | Chiara Saroli Palumbo | Received |
FRI-479 | Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France | Sylvie Deuffic-Burban | Received |
FRI-480 | Systematic screening in an ongoing cross-sectional epidemiological study on hepatitis C high-risk populations in Trondheim city, Norway | Therese Svendsen | Received |
THU-480 | Liver stiffness based model predicts portal hypertension, esofageal varices and hepatocellular carcinoma in caucasian patients with hepatitis B virus-related cirrhosis responsive to antiviral therapy | Claudia Chialà | Received |
SAT-480 | Circulating Fibroblast Activation Protein activity as a liver fibrosis biomarker in NAFLD | Geoffrey William McCaughan | Received |
THU-481 | Variability of intrahepatic fat distribution and optimal measurement of hepatic fat amount using MRI proton density fat fraction | Dae Won Jun | Received |
SAT-481 | Point shear wave elastography (ElastPQ) is a reliable non-invasive tool for the diagnosis and characterisation of portal hypertension | Matteo Rosselli | Received |
FRI-481 | Prevalence of end of life criteria in patients with liver disease in South West England | Ulrich Thalheimer | Received |
FRI-482 | High levels of transmission of HCV infection among people who inject drugs in Greece | Vana Sypsa | Received |
SAT-482 | Prospective comparison of shear-wave elastography, CAP and conventional ultrasound for non-invasive detection and grading of steatosis | Maxime Ronot | Received |
THU-482 | Acoustic radiation force impulse elastography combined with ultrasound spleen platelets portal vein doppler score in variceal screening: Improved performance compared with baveno VI criteria for avoidance of endoscopy in cirrhotics | David Ian Sherman | Received |
THU-483 | The role of serial ARFI elastography in confirming remission in active autoimmune liver disease: a controlled study with long follow up | David Ian Sherman | Received |
FRI-483 | High prevalence of chronic hepatitis C in injecting drug users in Tanzania, East Africa: a neglected burden of disease | Zameer Mohamed | Received |
FRI-484 | Novel PCR-based method to detect fungal colonization of ascites, bile and duodenal fluid in patients with acute on chronic liver failure (ACLF) or after orthotope liver transplantation (OLT) | Adam Herber | Received |
THU-484 | ElastPQ shear-wave elastography compared to fibroscan transient elastography for fibrosis staging in patients with NAFLD | Davide Roccarina | Received |
SAT-484 | The point of care 13C-Methacetin breath test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology | Mitchell L. Shiffman | Received |
SAT-485 | The hidden burden of hepatitis C related advanced liver disease in the community | Nadeem Iqbal | Received |
THU-485 | Delayed decrease of splenic stiffness in chronic hepatitis C virus patients receiving direct-acting antivirals | Dina Attia | Received |
FRI-485 | Model for end stage liver disease score dynamics in NASH patients awaiting liver transplantation and waitlist outcomes | W. Ray Kim | Received |
FRI-486 | Model for end stage liver disease score dynamics in patients awaiting liver transplantation and waitlist outcomes | W. Ray Kim | Received |
THU-486 | Urinary metabotypes in patients with chronic hepatitis C virus infection as revealed by nuclear magnetic resonance-based metabolomics | Elisa Biliotti | Received |
SAT-486 | Attenuation coefficient measurement as novel real time ultrasound alternative to CAP (fibroscan) | Nataliia Marunchyn | Received |
SAT-487 | How to combine blood test and elastography to stage liver fibrosis in chronic hepatitis C? | Paul Cales | Received |
FRI-487 | External validation of the HCC-MELD score for patients with hepatocellular carcinoma waiting for liver transplantation | Alessandro Vitale | Received |
THU-488 | Noninvasive assessment of liver fibrosis and portal hypertension after viral eradication in post-transplant hepatitis C | Ezequiel Mauro | Received |
SAT-488 | Comprehensive NAFLD diagnosis based on a noninvasive metabolomic approach in a liquid biopsy | Puneet Puri | Received |
FRI-488 | Sofosbuvir based therapy for recurrent hepatitis C post liver transplantation: an Egyptian experience | Ayman Yosry | Received |
FRI-489 | The impact of multidisciplinary support to alcohol misusers at risk of alcohol relapse after liver transplantation | Barbara Lattanzi | Received |
THU-489 | Normal values of liver stiffness as measured by transient elastography: pooled individual participant data meta-analysis from 26 studies and 14,883 participants | Kymberly D. Watt | Received |
THU-490 | Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens | Federico Ravaioli | Received |
SAT-490 | Serum Pro-C3 combined with clinical parameters is superior to established serological fibrosis tests at identifying patients with advanced fibrosis among patients with Non-alcoholic fatty liver disease | Samuel Joseph Daniels | Received |
FRI-490 | A tele-health based technology can effectively triage liver transplant evaluations and minimize futile invasive testing in an integrated health deliver system | Binu John | Received |
FRI-491 | Prospective comparison of coefficient attenuation parameter and ultrasound for grading graft steatosis in a large real-life cohort of liver-transplant patients | Christiane Stern | Received |
SAT-491 | Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in obese patients with non-alcoholic fatty liver disease | Sander Lefere | Received |
THU-491 | DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods | Federico Ravaioli | Received |
THU-492 | Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients | Federico Ravaioli | Received |
FRI-492 | Cardiovascular risk and coronary artery calcium score after liver transplantation: study at fouth year | Claudia P Oliveira | Received |
SAT-492 | The assessment of liver fibrosis stage by two-dimensional shear wave ultrasound and transient elastography in patients with chronic liver disease | Sang Gyune Kim | Received |
THU-493 | Which are the best cut-off values for predicting different stages of liver fibrosis for 2D-SWE.GE in daily practice? | Felix Bende | Received |
SAT-493 | Circulating serum exosomal microRNA-203 as a non-invasive biomarker for predicting prognosis in hepatocellular carcinoma | Se Young Jang | Received |
FRI-493 | Auxiliary liver transplantation for acute liver failure: a model of competition between regeneration and apoptosis | Clémence Hollande | Received |
FRI-494 | Preoperative intra-platelet serotonin levels are associated with early disease recurrence after liver resection in humans | David Pereyra | Received |
THU-494 | Non-invasive assessment of liver fibrosis by point share wave elastography in primary biliary cholangitis: comparison with fibroscan and fibrosis scores | Francesca Saffioti | Received |
SAT-495 | Community Approach Targeting Cirrhosis and Hepatocellular carcinoma (CATCH): Community prevalence of advanced fibrosis in viral hepatitis | Stephen Bloom | Received |
THU-495 | Predictive value of S-GGT for severe liver disease in the general population – a population-based cohort study with over a decade of follow-up | Fredrik Åberg | Received |
SAT-496 | Transient Elastography has limited efficacy for fibrosis assessment in End Stage Renal Disease patients on maintenance haemodialysis with suspected liver disease | Sunil Taneja | Received |
THU-496 | Assessment of fibrosis markers in a large cohort of chronic hepatitis B patients in Ethiopia | Hailemichael Desalegn | Received |
FRI-496 | Impact of sustained virologic response on liver fibrosis in recurrent hepatitis C after liver transplantation | Ezequiel Mauro | Received |
FRI-497 | Leaky gut does not affect the risk of infectious complications and survival in liver transplant recipients: comparison with cirrhotic patients and healthy individuals | Francesca Romana Ponziani | Received |
SAT-497 | Point shear wave elastography method for assessing liver stiffness in different etiologies of liver diseases – a prospective study | Tarek Saadi | Received |
SAT-498 | The novel point shear-wave elastography method ElastPQ is accurate for non-invasive evaluation of liver fibrosis and portal hypertension | Theresa Bucsics | Received |
THU-498 | Non-invasive multiparametric MRI (LiverMultiScanTM) effectively excludes NASH and liver fibrosis in at risk patients | Rajarshi Banerjee | Received |
FRI-498 | Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogues is highly effective and reduces cost for hepatitis B prophylaxis after liver transplantation | Rob Bielen | Received |
THU-499 | Characterisation of liver fat in the UK biobank cohort | Rajarshi Banerjee | Received |
SAT-499 | Impact of hepatic steatosis and controlled attenuation parameter (CAP) on accuracy of fibrosis staging using transient elastography | Thomas Karlas | Received |
SAT-500 | The effect of liver steatosis on non-invasive measurement of liver iron concentration by spin-density projection assisted R2-MRI (FerriScan) | Tim Guy St Pierre | Received |
THU-500 | Predicted prevalence and stratification of non-alcoholic fatty liver disease in a large population using non-invasive multiparametric MRI | Rajarshi Banerjee | Received |
FRI-500 | Acute rise in delta model for end-stage liver disease as a prognostic risk factor for post-transplant mortality: an analysis of a national registry | George Cholankeril | Received |
THU-501 | Novel mapping of fibrosis and hepatic inflammation in NASH patients with dual R2 MRI relaxometry | Claudia P Oliveira | Received |
SAT-501 | Clinical and prognostic associations of liver volume determined using computed tomography in patients with cirrhosis | Tiong Yeng Lim | Received |
THU-502 | Hepatic iron overload analysis bymagnetic resonance imaging in a non-alcoholic fatty liver disease population | Claudia P Oliveira | Received |
SAT-502 | Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein as a serum biomarker for disease severity in non-alcoholic fatty liver disease | Wah Kheong Chan | Received |
FRI-503 | Laparoscopic liver resection for hepatocellular carcinoma located in segments 7 or 8 | Hanisah Guro | Received |
THU-503 | Serum immunoglobulin levels are related to histological severity of primary biliary cholangitis | Huan Wang | Received |
SAT-503 | Collagen formation and degradation biomarkers identify advanced fibrosis in NASH patients | Yi Luo | Received |
SAT-504 | A novel non-invasive Golgi protein 73 (GP73)-based model accurately diagnoses significant fibrosis in chronic liver disease | Zhujun Cao | Received |
THU-504 | Dynamic of liver stiffness values by means of transient elastography in patients with hepatitis C virus liver cirrhosis undergoing Interferon free treatment | Ioan Sporea | Received |
FRI-504 | Effects of liver transplantation on cardiac function in patients transplanted for NASH cirrhosis | Haripriya Maddur | Received |
LBP-505 | Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe | Alison D. Marshall | Received |
LBP-506 | B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cholangitis: a randomised controlled trial (RITPBC) | Amardeep Khanna | Received |
LBP-507 | One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection | Andrew Vaillant | Received |
LBP-508 | Direct-acting antivirals for hepatitis C do not increase the risk of hepatocellular carcinoma recurrence after locoregional therapy or liver transplant waitlist dropout | Annsa C Huang | Received |
LBP-510 | Preventing decompensation of cirrhosis with clinically significant portal hypertension and without high-risk varices: a new indication for non-selective beta-blockers (NSBB) | Candid Villanueva* | Received |
LBP-512 | Circulatory microRNA-142 as potential biomarker of disease progression in paediatric cystic fibrosis-associated liver disease | Diego A. Calvopina | Received |
LBP-513 | A Notch receptor-selective Jagged1 mutation causes an Alagille syndrome phenotype in mice | Emma R Andersson | Received |
LBP-514 | Baseline neutrophil to lymphocyte ratio can identify favourable corticosteroid response in alcoholic hepatitis | Ewan Forrest | Received |
LBP-515 | Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH | George Kemble | Received |
LBP-516 | 13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis | Guadalupe Garcia-Tsao | Received |
LBP-521 | Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis | Jolanta Skarbaliene | Received |
LBP-522 | Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study | Juergen Rockstroh | Received |
LBP-523 | A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis | Laura Turco | Received |
LBP-524 | Severe periodontitis predicts higher cirrhosis mortality | Lea Ladegaard Grønkjær | Received |
LBP-525 | Epidemiology of hepatitis C infection in children and young people in the UK | Line Modin | Received |
LBP-526 | Safety, tolerability and treatment effectiveness of chronic hepatitis B patients with pradefovir: a phase 1b multiple ascending dose study | Liu Jingrui | Received |
LBP-528 | Incidence and prevalence of recorded non-alcoholic fatty liver disease in four large European primary care databases covering 21.9 million adults | Myriam Alexander | Received |
LBP-529 | Worldwide lack of early referral of patients with alcoholic liver disease: results of the global alcoholic liver disease survey (GLADIS) | Neil D Shah | Received |
LBP-530 | Degree of liver fibrosis regression predicted by transient elastography after cure of chronic hepatitis C with direct acting antivirals is overestimated but confirmed by liver biopsy | Paul Pockros | Received |
LBP-531 | The roles of glycogen synthase kinase-3 genes in liver functions | Prital Patel | Received |
LBP-532 | Potential viral triggers for pediatric and adult autoimmune hepatitis | Richard Taubert | Received |
LBP-533 | Prospective prevalence study of adult NAFLD/NASH utilizing multi-modality imaging compared with liver bopsy | Stephen A. Harrison | Received |
LBP-536 | Regulation of the mechanistic target of rapamycin complex 1 (mTORC1) - nuclear hormone receptor signaling by bile acids | Tarek Moustafa | Received |
LBP-537 | Impact of NASH, gender, fasting glucose and body mass index on the liver fibrosis transition rate (FTR) in metabolic liver disease (MLD) | Thierry Poynard | Received |
LBP-538 | Preclinical study of a combinatorial RNAi/vaccination therapy as a potential cure for chronic hepatitis B | Thomas Michler | Received |
LBP-539 | Autologous liver transplantation in end-stage hepatic alveolar echinoccossis with 51 patients´ experience--where do we stand? | Tuerhongjiang Tuxun | Received |
LBP-540 | Propranolol versus endoscopic variceal ligation in patients with cirrhosis and ascites- a randomised controlled trial | Virendra Singh | Received |
LBP-543 | iPLA2beta protects aged male mice from liver fibrosis and intestinal atrophy by modulating phospholipid and enterohepatic bile acid metabolism | Walee Chamulitrat | Received |
LBP-544 | High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4 | Zobair M Younossi | Received |
LBP-545 | Handouts payed by paypal | Daniel Zaldumbide | Received |
19-23 April 2017 Amsterdam
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|